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CHAPTER I 
 
INTRODUCTION 
 
Evolutionary development of innate and adaptive immunity 
The immune system evolved with the decent of colonial metazoans as a means 
to recognize members of the species (sometimes allotypes, e.g., ascidians) and 
in defence against toxic substances, parasites and pathogens (1). Consequently, 
the immune system of each species coevolved with the environmental factors of 
the niche they occupy. This has led to specialization such that immune response 
outcomes often vary between different organisms even when basic mechanisms 
of immune recognition have remained the same (2). For example, the human 
immune system is further specialized by virtue of the signature microbiome with 
which the individual lives in commensal or symbiotic harmony. Nonetheless, 
studies on mice and nonhuman primates have significantly advanced our 
understanding of the basic principles of immune recognition and response that 
have laid the foundation for understanding human immunology (3-5).  
Vertebrates utilize innate and adaptive defence mechanisms against 
foreign microbes and pathogens as well as toxic substances. Although the innate 
mechanisms are ancient and predate vertebrate descent, the adaptive immune 
system is more recent and appeared with the descent of aquatic vertebrates 
around 500 million years ago (6). The two systems, innate and adaptive, 
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nonetheless depend on each other to orchestrate an effective antigen-specific 
effector response (3).  
But for the discovery of the genetic restriction of histocompatibility (blood 
groups and major histocompatibility complex (MHC), alloantigens) and 
immunosuppression, every human transplant would have remained an 
experiment whose outcome could seldom be predicted with certainty (7). 
Nonetheless, despite histocompatibility testing and immunosuppression, allograft 
outcome in many recipients remains uncertain. The innate immune responses 
early in allograft life and immunity to minor histocompatibility alloantigens (HAgs) 
affect greatly the function of transplanted organs (8). 
T cell responses are primed when the innate immune response culminates 
in the display of processed antigens by antigen presenting cells (APCs) in the 
context of MHC-encoded class I and class II molecules (9). Class I molecules, 
which regulate cytotoxic T lymphocyte (CTL) functions, present 
endogenous/cytoplasmic antigens, whereas class II molecules, which control T 
helper (TH) cell functions, present exogenous/extracellular antigens (10, 11). 
Notwithstanding this dichotomy, CTL responses can also be primed by class I-
restricted extracellular antigens in a previously described, but still not entirely 
defined process termed cross-presentation (11, 12). Likewise, studies of TH cell 
responses to alloantigens, cancers, viruses and cytosolic bacteria have 
suggested that class II molecules present certain cytoplasmic antigens (13-24) in 
a poorly defined process termed indirect presentation.  
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 MHC class II processing pathway displays antigens originating from 
endogenous (direct) and indirect (dead or dying cells) sources. Direct antigen 
presentation is dependent on several mechanisms which facilitate cytoplasmic 
antigen supply to the lysosomal compartment. Such mechanisms include 
autophagy and, for few reported antigens, proteasome-dependent processing 
pathway (20, 25, 26). On the other hand, indirect presentation is the major 
pathway for antigen supply for loading class II molecules with antigenic peptides. 
According to the consensus based on available evidence, exogenous antigens 
that are captured through endocytosis or phagocytosis travel to the lysosomes 
where resident proteases facilitate antigen processing (27). In this regard, the 
characterization of minor HAgs, bacterial and tumour antigens have unravelled 
novel processing mechanisms as well as a better understanding of indirect 
presentation. Indirect presentation of class II antigens is a frequently occurring 
and fundamental process of immune recognition. 
The class II processing pathway is primarily specialized for presentation of 
exogenous antigens, which, upon internalization, are targeted to lysosomes (28, 
29). However, recent studies have suggested that a large number of class II-
restricted antigens originate from cytoplasmic proteins derived from infected, or 
tumour cells which do not express class II molecules (30). Such cytoplasmic 
antigens require indirect presentation by professional APC in order to elicit TH cell 
responses (31). However, internalized cytoplasmic antigens are frequently 
targeted to the proteasomes and transported to the lumen of the endoplasmic 
reticulum (ER) via transporter associated with antigen processing (TAP). 
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Therefore, internalized antigens need to seep into the cytoplasm and escape 
lysosomal processing through the process of cross-presentation (32, 33).  
Even though a lot is known regarding cross-presentation, mechanisms are 
incompletely understood. Interestingly, very little is known about rules that govern 
indirect presentation of self and foreign cytoplasmic antigens that are from dead, 
dying and tumour cells by class II molecules in professional APCs. The ensuing 
overview discusses the currently understood principles by which antigens are 
processed and assembled with class II molecules.  
 
MHC class II-restricted antigen processing pathway 
MHC class II  heterodimers assemble in the lumen of thr ER with the help of 
calnexin (CNX) and invariant chain (Ii) (34, 35). Class II molecules critically 
depend on the associated Ii to facilitate their transport to the Golgi apparatus 
where their N-glycans are trimmed and modified prior to egress and transport  to 
the lysosomal compartment (36).  
Class II  heterodimers couple with a trimeric Ii scaffold, which contains 
a di-leucinal or leucinal-isoleucine targeting motif within its cytoplasmic tail that 
directs the class II-Ii complexes to the late endosomal/lysosomal compartment. Ii 
is a non-polymorphic, type II transmembrane protein consisting of a short N-
terminal cytoplasmic domain, ER transmembrane domain, a disordered segment, 
which binds and shields the class II peptide binding groove, and a C-terminal 
trimerization motif. Upon Ii trimerization, three class II  heterodimers bind to 
the trimeric Ii scaffold, thus forming a trimer of trimeric (class II +Ii) complexes. 
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Ii not only prevents peptide binding to class II molecules in the ER, but also 
prevents other ER chaperones from binding to the heterodimers and retaining 
them in the ER (36-38). Finally, upon entry into the lysosomes, Ii is cleaved with 
the help of various peptidases through a series of cleavage events (discussed 
below).  
Upon exit from the ER, class II-Ii complexes negotiate the Golgi apparatus 
and traffic into the TGN (39). There are several paths that the class II +Ii 
complexes can take. First, a small fraction of the complexes exit directly to the 
cell surface, where they are rapidly internalized to early endosomes and loaded 
with class II-restricted peptides in a H-2DM-independent manner (40, 41).  
Second, class II-Ii complexes may traverse the early endosomal 
compartment to acquire class II-restricted peptide cargo. The early endosomes 
play a significant role in determining the migration and eventual fate of class II 
molecules (42). The MHC class II vesicles (CIIV), a compartment rich in class II 
molecules, resembles the early endosomes but is distinct from those originating 
by endocytosis (43). CIIV is distinct from the MHC class II compartment (MIIC), 
which is a multivesicular structure composed of late endosomes and lysosomes 
(44). CIIV may therefore, represent an intermediary compartment for peptide 
loading and the subsequent egress of class II molecules to the cell surface (45). 
DCs, but not B cells contain CIIVs, suggesting different traffic routes for class II 
molecules to the cell surface in different cell types (10).  
According to the third, which is considered the most significant pathway, 
class II-Ii complexes may be directly targeted to the MIIC for loading with 
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antigenic peptides. The MIICs play a greater role in loading class II molecules 
with antigenic peptides compared to the CIIVs (44). This difference is mostly due 
to the abundance of lysosomal enzymes and H-2DM in the MIICs and their near 
absence in the CIIVs. For a long time, it was unclear how peptide-loaded class II 
molecules exit MIICs and travel to the cell surface, i.e., whether via CIIV or by 
direct shuttling to the cell surface. In immature DCs, the majority of class II 
molecules are retained in the MIIC, and directed to the cell surface upon cytokine 
stimulation (46). When immature DCs are stimulated with lipopolysaccharide 
(LPS), or other stimuli, MIICs undergo morphological changes ultimately resulting 
in tubule formation. Tubules are transient in nature and only found in close 
proximity to the plasma membrane. Next, they fuse with the plasma membrane to 
allow class II display on the cell surface (44, 47).   
Upon class II-Ii entry into the lysosomes, Ii degradation proceeds through 
a stepwise process regulated by various proteases. The first step is catalyzed by 
leupeptin-insensitive cysteine/aspartate proteases, followed by the action of the 
leupeptin-sensitive cysteine/aspartate proteases, cathepsin S and other 
cathepsins (48). Cathepsin L plays a significant role in Ii proteolysis specifically in 
cortical thymic epithelial cells (cTECs) as demonstrated by the defective thymic 
CD4+ T cell selection in cathepsin L-deficient mice (49). On the other hand, 
cathepsin S has been shown to play a significant role in generating class II-
restricted epitopes in B cells and DCs, since both cell types lack the enzymatic 
activity attributed to cathepsin L (50, 51).  
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H-2DM (HLA-DM in humans), a non-classical class II molecule, catalyses 
the enzymatic reaction that displaces CLIP with an antigenic peptide (52, 53). H-
2DM is synthesized in the ER and then transported to the lysosomal 
compartment with the help of a tyrosine-based motif in the cytoplasmic tail of H-
2DM . H-2DM  and  chains have homology with corresponding chains of the 
classical class II molecules; however the sides of the peptide binding groove of 
H-2DM are closely apposed to each other which leaves no space for peptide 
binding (54). Class II and H-2DM require direct contact for peptide exchange. H-
2DM is suggested to keep empty and unstable class II molecules in a 
conformation permissive for peptide binding (55). In the absence of H-2DM, class 
II molecules are unstable, aggregate and, hence, are destined for degradation 
(56, 57).  
Thus, class II-Ii migration from the ER, Ii proteolysis, H-2DM-mediated 
removal of CLIP and loading with the antigenic peptide are highly regulated 
processes. At the end of this series of events, a peptide MHC II complex travels 
to the cell surface carrying 12—20 amino acid residues long antigenic peptide 
(58). Such peptides are mainly generated within the lysosomes. Peptide (p)/class 
II complexes are presented on the cell surface for an appraisal by TH cells.  
 
Mechanisms governing class II processing and presentation in DCs 
Professional APCs such as B cells, macrophages (M ) and DCs differ in class II 
expression in their immature state. B cells and M  constitutively express copious 
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amounts of class II, while DCs express significantly lower levels of these 
molecules (59). 
DCs have a crucial role in regulating various aspects of both innate and 
adaptive immune responses. DCs were first described by Steinman and Cohn in 
1973 (9). Since then, it was determined that DCs and to a lesser extent M  
participate in both antigen cross- and indirect presentation, thus raising questions 
regarding DC-specific rules governing class II loading with antigenic peptides. 
During DC maturation, cells are transformed from those that capture 
(phagocytosis, endocytosis, macropinocytosis) and process antigens, to those 
which present short processed peptides to T cells for an appraisal (60).  
Immature DCs were first thought to be inefficient in class II-restricted 
antigen presentation. However, new evidence suggests that immature DCs can 
also load class II molecules with peptides and display them on the cell surface, 
suggesting that lysosome-resident class II are not retained, but instead p/class II 
complexes are transiently expressed at the cell surface (61). Such short lived 
class II molecules are rapidly endocytosed and degraded in the lysosomes (61).   
The repertoire of class II-restricted peptides presented by immature and 
mature DCs do not differ as judged by the characteristics of naturally processed 
ligands eluted from class II molecules expressed by the differentiated states of 
the APCs. Nonetheless, differences are in the amount of CLIP-associated class II 
molecules, which is greater in the immature DCs (62).  
In maturing DC, newly synthesized class II molecules originate from MIIC. 
Also, during maturation, there is a transient, ~18-hour long, increase in class II 
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synthesis. At the same time, there is a transient increase in proteolytic activity 
upon antigen capture (61). Exported class II molecules on the cell surface are 
long-lived, with cell surface half-time which is greater than 150 hours for 
immunodominant antigens, while immunorecessive antigens are presented with 
a half-life of ~10 hours. The half-life of peptide-class II complexes is a critical 
factor that dictates immunodominance and subsequent TH cell responses (63). 
Strikingly, recent reports have suggested that even mature DCs retain the 
capacity to continue with antigen capture and processing (64, 65). 
The cytoplasmic tail of the class II -chain is ubiquitylated in murine 
immature DCs, which allows class II recycling from the cell surface. The number 
of ubiquitylated class II molecules in DCs decreases following maturation, 
resulting in the accumulation of MHC class II molecules at the cell surface (66).  
In sum, emerging evidence indicates that immature DCs present class II-
restricted antigens and participate in maintaining peripheral tolerance to self-
antigens. This contrasts earlier reports, which suggested no class II molecules 
expressed by immature DCs. Upon antigen capture, class II molecules on the 
cell surface are replaced with newly synthesized molecules, and remain there for 
prolonged periods of time. Also, contrary to earlier reports, recent evidence 
indicates that mature DCs do indeed retain some capacity to capture new 
antigens and present them to T cells (64, 65).  
There are several pathways that are utilized for presentation of exogenous 
and endogenous class II-restricted antigens. The following discusses the 
principles that governing antigen processing within class II pathway.  
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MHC class II-restricted processing of exogenous antigens in the lysosomes  
Disulfide bonds maintain protein structural stability and aid in protein function. 
The reduction of disulfide bonds within antigens by -interferon-inducible 
lysosomal thiolreductase (GILT) is a critical initial step for protein unfolding and 
proteolysis (67). The enzymatic action of GILT requires an acidic pH. Many 
tumors down regulate GILT expression perhaps for evading host immunity (68).  
Processing of antigens is accomplished with the help of various 
exopeptidases and endopeptidases, namely cathepsins (69). Here are 
summarized basic examples which govern cathepsin activity and their complex 
roles in antigen processing within the lysosomes: 
- Specific cathepsins can be present at the mRNA as well as protein 
level in APC, but they do not necessarily display enzymatic activity. For 
example, DCs express cathepsin L, but it is not functional (49, 70). 
- Cathepsins are greatly affected by the pH of their resident vesicle: low 
pH positively affects their activity (69). 
- Another mechanism for regulating class II-restricted antigen 
processing is through low expression of lysosomal proteases in 
immature DC versus M . Upon DC activation, their expression rises to 
levels comparable to M  (69).  
- Individual cathepsins regulate activity of other proteases; e.g., 
cathepsin S in B cells lowers expression of cathepsin L, and also 
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affects GILT activity. Cathepsin L, on the other hand, affects 
cathepsins C and D in cTECs (71).  
Therefore, class II Ag processing within the lysosomes includes a series of 
events, which are dependent on complex relationships between enzymes. Ag 
processing differs among professional APCs, thymic epithelium and activated 
epithelial cells.  
 
Autophagy: a mechanism that provides cytoplasmic antigens for MHC 
class II-restricted presentation  
Class II molecules are capable of binding and presenting peptides derived from 
endogenous proteins. Class II-restricted peptide elution and sequencing 
experiments have revealed that more than 20% of the naturally processed 
ligands originate from cytoplasmic proteins. A number of class II epitopes are 
also derived from cytosolic, plasma membrane and secretory vesicular proteins 
(72, 73).  
Macroautophagy is constitutively active in cells of immune and non-
immune system cells and tissues. The lysosomal compartment continuously 
receives input from the cytoplasm via macroautophagic mechanisms (74). 
Accordingly, the targeting of antigens to autophagosomes leads to enhanced 
class II-restricted antigen presentation, which in turn regulates TH cell responses 
to cytoplasmic antigens (20). A related process, chaperone-mediated autophagy 
(CMA), mediates transfer of proteasomal substrates to the lysosomal 
compartment (21).  
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Autophagy involves stress-induced formation of double membrane 
structures, which non-specifically engulf cytoplasmic antigens, or damaged 
cellular organelles. During the initiation of this process, a damaged organelle, or 
a portion of the cytosol is encased in a structure termed the isolation membrane 
or phagophore. The phagophore then becomes enlarged during the elongation 
stages by the addition of new membrane — the origin of which is still unclear. 
The phagophore seals to form an autophagosome. Next, autophagosomes fuse 
with lysosomes where the cytoplasmic material is delivered for further processing 
(Figure 1) (75, 76). 
Key players that regulate autophagy are the serine/threonine kinases, 
mammalian target of rapamycin as well as the class I and class III 
phosphoinositide 3‑kinases. The initial steps of autophagosome formation 
include autophagy related 12 (Atg12) activation, which depends on Atg7 and 
Atg10. Ultimately, a complex of Atg12, Atg5 and Atg16 is formed. These 
molecules are accompanied by Atg4 activated Atg8 (also called light chain 3-II 
(LC3-II)), and the complex is present on the surface of newly formed 
autophagosomes. Next, LC3-II translocates to the centre of  autophagosomes 
and is degraded following fusion with lysosomes to form autolysosomes (77). 
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Figure 1. Macroautophagy donates cytoplasmic antigens to the lysosomal 
compartment for processing and loading MHC class II molecules with 
antigenic peptide. Cytoplasmic proteins are engulfed by isolation membrane 
which gives rise to autophagosomes. Autophagosomes fuse with lysosomes and 
deliver cytoplasmic proteins for further processing: GILT reduces disulphide 
bonds within proteins, while cathepsins S, as well as other cathepsins, further 
degrade protein to peptide fragments. Upon loading with antigenic peptide, 
p/class II complexes egress to the cell surface. 
CatS, cathepsin S; GILT, -interferon-inducible lysosomal thiol reductase; Ly, 
lysosomes; MHC, major histocompatibility complex; pm, plasma membrane. 
Adapted from (75). 
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Emerging evidence suggests that numerous microbes utilize various 
mechanisms to affect autophagy while residing in the cytoplasm of infected cells. 
One of the first reported autophagy-dependent class II antigens was 
derived from the Epstein-Barr virus nuclear antigen 1 (20, 78). Furthermore, HIV-
1 inhibits autophagy in DCs. 
Other pathogens—including Shigella flexneri and Legionella pneumophila, 
as well as Herpes simplex virus-1 (HSV-1)–have developed similar mechanisms 
to evade the immune system. They are able to evade their degradation in 
autolysosomes and, in some cases, even use autophagic vesicles for 
proliferation (79, 80). 
Autophagy has been implicated in generating tumour-derived class II-
restricted antigens. Class II presentation of peptides derived from a tumour 
antigen, Mucin gene 1, and neomycin phosphotransferase II was affected by 
blocking autophagy with the specific pharmacological inhibitor, 3-methyladenine 
(3-MA) (81).  
CMA also contributes to the pool of cytoplasmic class II-restricted 
antigens. Proteasomal processing provides substrates for heat shock protein 70 
complex (Hsc70), which stabilizes antigens and chaperones them to the 
lysosomal compartment (21).  
Blum and coworkers found that ectopically expressed glutamate 
decarboxylase in a B cell line, which is normally expressed selectively within 
insulin-producing  cells in the islets of Langerhans, becomes a proteasomal 
substrate. The resulting proteasomal product is delivered to lysosomes upon
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Figure 2: Chaperone mediated autophagy: HSP70 captures proteasomal 
products and transports them to LAMP-2a+ lysosomes for loading on MHC class 
II molecules. p/class II complexes egress to the cell surface. At the same time, 
proteasomal products are also the main source of antigens for the class I 
pathway, where HSP90 shields and delivers them to TAP which imports them to 
the ER lumen for processing by ERAAP. 
CatS, cathepsin S; ER, endoplasmic reticulum; ERAAP, ER associated 
aminopeptidase associated with antigen processing; GILT, -interferon-inducible 
lysosomal thiol reductase; HSP- Heat shock protein; LAMP-2a, lysosomal 
associated membrane protein-2a; Ly, lysosomes; MHC, major histocompatibility 
complex; pm, plasma membrane; TAP, transporter associated with antigen 
processing. Adapted from (75). 
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Hsc70 binding to LAMP-2a positive lysosomes. LAMP-2a is a highly glycosylated 
lysosomal transmembrane protein. Interestingly, LAMP2a and Hsc70 complex do 
not affect the presentation of exogenous class II-restricted antigens (Figure 2) 
(82).  
Thus, both macroautophagy and CMA are known to contribute to the pool 
of cytoplasmic, class II-restricted antigens and, hence, regulate presentation of 
cytoplasmic antigens of microbial origin. 
 
Components of the MHC class I processing pathway affect 
presentation of cytoplasmic, class II-restricted antigens 
Autophagy is not the sole source which supplies cytoplasmic antigens to 
lysosomes. A number of cytoplasmic class II-restricted antigens are independent 
of this process, which raises questions regarding factors that critically affect their 
presentation. Class II-restricted antigens derived from cytoplasmic bacteria, 
Listeria monocytogenes and Francisella tularensis, for example, critically depend 
on indirect presentation because they damage and destroy the host cells that 
they infect (83). Infected or dying cells are perhaps phagosytosed by APCs to 
allow indirect presentation of class II-restricted antigens. However, it is less well 
understood as to how cytoplasmic antigens donated by another cell become 
indirectly presented by class II. It is generally assumed that antigens donated by 
another cell are acquired and indirectly presented by APCs by a mechanism 
similar to direct presentation. This is because donated antigens are generally 
phagocytosed, endocytosed or pinocytosed and eventually enter the 
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endo/lysosomal compartment. As described above, these vesicles contain the 
processing enzymes and accessory proteins that facilitate indirect antigen 
presentation by class II molecules (32). Thus, indirect presentation is a variation 
on the direct presentation mechanism of extracellular microbes and their 
products. Nevertheless, many donated cellular antigens find their way into the 
cytoplasm. The mechanism by which such antigens are presented by class I 
molecules is incompletely understood.   
Most studies thus far have only focused on examining processing 
properties of overexpressed cytoplasmic proteins in cell lines that leads to direct 
presentation by class II molecules (84). Such studies have revealed many class 
II-restricted cytoplasmic antigens. Examples include class II-restricted antigens 
derived from measles virus matrix and nucleocapsid proteins (85). Other 
examples include cytoplasmic tumour antigens such as human melanoma 
derived mutated forms of CDC27 and triosephosphate isomerase (24). 
Recent studies have described a role for proteasomes in generating class 
II-restricted cytoplasmic epitopes. For example, a B cell line was transfected with 
a mutant form of Ig  (named SMA, which is the causative agent of light chain 
amyloidosis) and shown to depend on proteasomal processing for presentation 
of a SMA-derived class II-restricted epitope (Figure 2, top right). However, the 
presentation of exogenously added protein was not affected by proteasome 
inhibition with lactacystin, but was inhibited by lysosomal alkalinization, 
suggesting distinct, but possibly partially overlapping routes of antigen 
processing. Another independent study has demonstrated that ovalbumin (OVA) 
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introduced into the cytosol of APCs by osmotic shock, becomes a proteasomal 
substrate prior to being loaded onto class II molecules (86). This suggests that 
proteasomal processing is a prerequisite for efficient presentation of some 
cytosolic class II antigens, which are not dependent on autophagy or CMA.  
However, the question still remains whether other components of the class 
I pathway—such as TAP and ERAAP (ER-associated aminopeptidase 
associated with antigen processing)—affect the pool of presentable class II-
restricted antigens. Two TH cell epitopes from two influenza virus glycoproteins, 
hemagglutinin and neuraminidase, were shown to depend on both the 
proteasomes and TAP for recognition by class II-restricted TH cells. TAP was 
required to transport both these class II-restricted epitopes into recycling 
endosomes where they were loaded on class II (87). Likewise, endogenously 
expressed hen egg lysozyme (HEL)-derived class II-restricted antigen required 
TAP function (88). Also, TAP is required for the loading of an overexpressed 
short cytosolic peptide derived from influenza nucleoprotein onto class II in a 
human B cell line (89). Thus, components of the class I-restricted antigen 
processing pathway, such as proteasomes and TAP, impact the presentation of 
cytoplasmic antigens by class II molecules. These studies have addressed the 
role of the class I-restricted antigen processing pathway in direct presentation of 
cytoplasmic, class II-restricted antigens. They, however, do not provide a 
mechanism(s) underlying indirect presentation of infected, tumour or allogeneic 
cells that are presented by recipient class II molecules. 
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Donor cell-derived cytoplasmic class II-restricted antigens acquired by 
recipient cells can seep into the cytoplasm where they may be exposed to the 
class I-restricted antigen processing pathway. In order to understand which 
factors affect indirect presentation of cytoplasmic antigens, a description of the 
currently purported mechanisms underlying class I-restricted antigen cross-
presentation is discussed below. These mechanisms may shed light on factors 
that might significantly affect indirect presentation of cytoplasmic bacterial, 
tumour and allogeneic antigens.  
 
MHC class I-restricted antigen processing pathway 
All nucleated cells express class I molecules on the cell surface. Class I 
molecules present short, 8—10 amino acid residues long, peptides to CTLs for 
an appraisal. This pathway is referred to as the endogenous antigen processing 
and presentation pathway because of its role in presenting peptides derived from 
cytoplasmic proteins (10). However, exogenously derived proteins regularly gain 
access, especially within DCs and become substrates for its processing 
components through a process termed cross-presentation (32). Consequently, 
naturally processed class I-restricted peptides are derived from both cytoplasmic 
and exogenous sources.   
 
The proteasome: structure and function 
The class I processing pathway depends on several key components. 
Proteasomes serve as the main source of peptides for class I binding as 
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determined by selective pharmacological agents. This leads to a sharp decrease 
in cell surface class I expression (11).  
Proteasomes are complex, multi-component particles that reside within 
the cytoplasm (90). They process proteins targeted for degradation. These are 
proteins with short half-life, or at the end of their life span (10). Proteasomal 
substrates also include freshly synthesized, but misfolded or misassembled 
protein complexes called ―defective ribosomal products‖ (DRiPs) (91). Most 
proteins are degraded by a three-step process which starts with ATP-dependent 
transfer of multiple ubiquitin molecules to the -amino group of lysine residues. 
This process is dependent on various ubiquitin ligases (92). The resulting 
polyubiquitinylated substrates serve as a signal for rapid destruction within the 
proteasomes (93). However, not all proteins require this initial step: proteasomes 
readily degrade cytoplasmic proteins which contain repetitive, conserved peptide 
sequences rich in proline (P), glutamic acid (E), serine (S) and threonine (T), 
called the PEST motif (94).  
 The 26S proteasomes are complex structures of ~2000 kD. They are 
comprised of two 19S regulatory units, each of ~700 kD, which flank a 20S core 
subunit of ~650 kD. The 19S cap is displaced with 11S regulatory subunit upon 
cellular activation with interferon-  (IFN- ). This and changes in the composition 
of the 20S core give rise to immunoproteasomes (95, 96). 
Under basal conditions, the 19S regulatory subunit is instrumental in 
recognizing and binding polyubiquitinylated proteins, as well as releasing free 
ubiquitin. The 19S subunit has ATPase activity, which is required to unfold 
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polypeptides and to direct them to the 20S core (97). The 20S core particle has a 
cylindrical structure. It is composed of 28 subunits arranged in four rings of 7 
subunits each. The  subunits form the two outer rings which are arranged in 
such a manner that they form a central opening. This opening directs unfolded 
polypeptides toward the centre of the proteasome (98). Proteolytic activity is 
attributed to the two central rings, which are composed of  subunits (94, 99). 
Peptides emerging from the proteasomes range from 4—24 amino acid residues 
in length. Only about 10% of the peptides produced by the proteasomes are ~8 
amino acid residues long; ~70% of the proteasomal products are of shorter 
length or are degraded to constituent amino acids, while ~20% are longer than 
those that typically bind to class I molecules (94).  
The immunodominant ovalbumin-derived class I peptide SIINFEKL is 
generated from 6—8% of available molecules, suggesting that this class I 
immunodominant epitope is readily destroyed by proteasomal processing. 
Consistent with this finding, Yewdell and colleagues have suggested that in the 
case of DRiPs, one class I epitope is generated from 104 misfolded proteins, 
which suggest that high DRiP frequency does not result in high abundance of 
specific epitopes. Also, the low frequency of proteasomal products would suggest 
that TAP-mediated translocation and class I peptide loading are not saturating 
processes (91). There are conflicting reports regarding cleavage patterns for the 
central  subunits. The 1 subunit predominantly cleaves peptide bonds after 
acidic amino acids (caspase-like activity), 2 after basic amino acids (trypsin-like 
activity) and 5 after hydrophobic amino acids (chymotrypsin-like activity). Thus, 
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murine proteasomes preferentially create peptides which contain hydrophobic 
and basic amino acids at the carboxyl terminus. Human proteasomes in general 
follow this pattern to produce a diverse set of peptides (100). The N-terminus of 
potential class I-restricted peptides is not necessarily created by the 
proteasomes as they oftentimes create peptides that are N-terminally extended 
with regard to peptides that are presented by class I molecules (101).  
Within the immunoproteasomes, 20S subunits 1, 5 and 2 are replaced 
with low molecular weight protein (LMP) 2 (i 1), LMP7 (i 5), and multicatalytic 
endopeptidase complex-like 1 (MECL-1, LMP10 or i 2), respectively (102, 103). 
These three subunits are incorporated into newly assembled 
immunoproteasomes, while they have no effect on components of existing 
proteasomes. Cells of the immune system constitutively express 
immunoproteasomes, while other cells assemble immunoproteasomes in 
response to IFN-  (94). 
Immunoproteasomes also contain the 11S subunit, which is ~200 kD in 
molecular mass; this subunit is called the proteasome activator complex (PA28). 
It consists of PA28  and PA28 . Thus, immunoproteasomes represent a mixture 
of complexes comprised of the 20S catalytic core as well as 19S and 11S 
regulatory subunits. PA28 does not increase the rate of protein degradation, but 
impedes peptide degradation to constituent amino acids by the 20S subunit (104-
106). 
Immunoproteasomes have increased protein cleavage rates. Various 
studies have shown that the absence of the immunoproteasome subunits results 
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in altered class I-restricted peptide repertoire. Also, LMP2- and LMP7-deficiency 
in animal models revealed that these subunits lead to class I peptide creation 
with hydrophobic and to a lesser extent basic C-terminal amino acids. Both 
LMP2- and LMP7-deficiency leads to greatly reduced numbers of CTL (94).  
Immunoproteasomes degrade a variety of proteins that are upregulated 
during inflammation in order to prevent formation of various, potentially harmful 
aggregates within the cytoplasm. Some of these proteins are damaged by the 
microbicidal reactive oxygen species (ROS) and require swift removal and 
clearance (107).  
A recent study has revealed the presence of a thymus-specific 
proteasome. cTECs in mice express the novel 5t subunit. In humans, this 
subunit is expressed by ~80% of the cTECs and in a subset of cortical DCs. This 
novel proteasomal subunit is involved in the process of thymic positive selection 
as these thymoproteasomes affect the repertoire of class II-restricted peptides 
(108).  
Proteasomes can also function as a polypeptide ligase. Within 20S 
complexes, novel class I epitopes are generated by excising a central peptide 
segment, followed by reconnecting the flanking regions to form a non-linear 
epitope. Furthermore, it was also demonstrated that proteasomal complexes can 
cleave nuclear protein and splice noncontiguous peptide segments in reverse 
order. Therefore, proteasomes not only cleave proteins into short segments, but 
also mix segments in direct or non-linear order followed by ligation of segments 
to produce novel noncontiguous class I epitopes (109).  
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The majority of peptides which exit proteasomes are immediately 
degraded by cytoplasmic proteases. Peptides that are shorter than 8 amino acid 
residues long are especially susceptible to such degradation. Cytoplasmic 
proteases which mediate this process are puromycin-sensitive aminopeptidase, 
bleomycin hydrolase, tri-peptidyl peptidase II, and thimet oligopeptidase (110-
112). Thus, proteasomes cleave proteins into short segments, many of which are 
further degraded. Those that escape degradation in the cytosol become 
substrates for the TAP transporter. 
 
TAP: structure and function 
Proteasomal products that are greater than 8 amino acid residues long can be 
customized for class I binding by further proteolytic processing in either the 
cytoplasm or the ER lumen upon transfer by the TAP transporter.  
Functional TAP molecules are heterodimers of TAP1 and TAP2 and are 
structurally classified as members of the ATP-binding cassette (ABC) transporter 
family (113). The role for TAP during antigen presentation has been established 
by creating TAP2- or TAP1-deficient cell lines and animal models, respectively, 
where most class I molecules are absent from the cell surface (114, 115). 
Each TAP subunit consists of ten transmembrane domains. Each TAP 
heterodimer consists of three structural domains found within six C-terminal 
transmembrane segments: pore, peptide binding and nucleotide binding domains 
(NBD). The remaining four transmembrane segments allow contact with the large 
peptide loading complex (PLC) via tapasin (116).  
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The central hydrophobic pore domain results from TAP1 and TAP2 
interaction. The peptide binding domain is located in the vicinity of the pore 
domain and is formed by cytoplasmic loop 2 and part of transmembrane segment 
6 originating from both TAP1 and TAP2. The mechanism of peptide binding to 
this domain is beginning to be elucidated since it is essential for TAP function 
(116, 117).  
NBD is located at the C-terminus of each subunit. ATP binds to specific 
Walker A and B motifs leading to triphosphate hydrolysis. The NBD is highly 
evolutionarily conserved and is present in various bacterial ABC transporters as 
well (118, 119). ATP hydrolysis causes substantial conformational changes to the 
transmembrane domains that form the pore. However, the exact nature of these 
changes is not yet understood (120). There are two hypothetical models for NBD 
function and peptide translocation along TAP heterodimers. According to the 
―processive clamp‖ model, a peptide and two ATP molecules bind specific sites 
on the TAP heterodimer. It is presumed that hydrolysis of both ATP molecules 
opens the pore domain to facilitate peptide import into the lumen of the ER. Once 
ADP is released, the two NBDs dimerize again and close the pore. Next, new 
ATP molecules bind to the NBD domain and the whole process is repeated 
(121). 
The second proposed model is called ―constant contact‖. In this model, 
NBD monomers never separate, but only one site binds ATP and allows NBDs to 
dimerize, while the other is open and empty. This way, one NBD dimer is always 
open, and closes only upon ATP hydrolysis of the other. Next, peptide drifts into 
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the lumen of the ER while ATP is not bound to the NBD. However, the exact 
mechanism is still not determined and is a matter of intense research (121).  
The N-terminal and the C-terminal amino acid residues determine peptide 
binding to human TAP, while the central part of the peptide does not bind to TAP. 
The central peptide segment forms a bulge, thus permitting promiscuity in TAP 
specificity for a large number of peptides. This allows TAP to bind a wide array of 
different peptides with high affinity (122).  
Murine and human TAP display high affinity for hydrophobic and basic C-
terminal amino acids and very little affinity for acidic amino acid residues. 
Peptides between 9—16 amino acid residues have the greatest affinity for TAP, 
even though peptides up to 40 amino acid residues in length bind TAP and are 
translocated to the ER lumen (123).  
Moreover, TAP is a target for viral evasion of CTL-mediated adaptive 
immunity. HSV-1 produces ICP47, and human cytomegalovirus (HCMV) product 
US6. Both bind to TAP and by steric hindrance prevent peptide import into the 
ER (124-127). Also, various metastatic tumours completely lack TAP, or express 
non-functional, mutated forms, suggesting a potential mechanism for evading 
tumour recognition by the immune system (128, 129).   
Newly synthesized class I heavy chains interact with immunoglobulin 
binding protein (BiP), CNX and calreticulin (CRT) in the lumen of the ER. 
Subsequently, CNX disassociates to allow binding with 2-microglobulin ( 2m), 
and an oxidoreductase, ERp57. The peptide loading complex is brought to close 
proximity of the TAP heterodimer via tapasin. Even though this peptide-loading 
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complex (PLC) is in indirect contact with TAP, class I molecules can be loaded 
with peptides in TAP-deficient cells. At the same time, the rate of peptide import 
into the ER by TAP is not affected in class I-deficient cells. Thus, peptide import 
into the ER and peptide loading on class I are two independent processes 
despite close association between TAP and PLC (130).  
Tapasin plays a very significant role during class I assembly with peptides. 
It increases the efficiency of class I-restricted antigen presentation by facilitating 
class I loading with high-affinity peptides, thus stabilizing cell surface p/class I 
complexes. At the same time, tapasin does not influence peptide binding to TAP 
and their influx into the ER lumen. Nonetheless, tapasin can regulate ERp57 
activity by preventing its dissociation from the PLC. Class I molecules loaded 
with low affinity peptides are retained in the ER. This process occurs through 
formation of a covalent bond between tapasin and ERp57, which is released only 
upon binding of optimal peptide cargo to class I molecules (131-133). A large 
number of peptides in the ER lumen require further customization prior to being 
loaded on class I, or need to be destroyed if they do not fit into the class I peptide 
binding groove.  
 
ER-associated aminopeptidase associated with antigen processing 
Proteasomes generate class I binding peptides that are N-terminally extended. 
The presentation of such longer peptides by class I molecules depends on the 
activity of additional peptidases both within the cytoplasm and within the ER. The 
ER-associated aminopeptidase associated with antigen processing (ERAAP) 
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plays a central role in customizing peptides to correct size for binding to class I 
molecules. Because ERAAP is indiscriminate, it can completely destroy potential 
epitopes. ERAAP functions as an N-terminal exopeptidase. Structurally, ERAAP 
belongs to a group of zinc-dependent metalloproteases. ERAAP is ubiquitously 
expressed in all nucleated cells and its expression is greatly increased in 
response to IFN-  (134, 135). 
ERAAP‘s role in customizing potential class I peptides was the subject of 
many studies. ERAAP deficiency leads to decreased cell surface expression of 
class I molecules by ~40—50%, depending on the class I allotype. Nonetheless, 
levels of class I expression between wild type and ERAAP-deficient cells became 
indistinguishable upon IFN-  treatment (136). For example, the expression of H-
2Ld molecules is lowered by ~80% in ERAAP-deficient cells compared to wild 
type cells. The reason for this lies in ERAAP‘s inability to cleave N-terminal X-Pro 
bond (X, any amino acid), a motif, which is found in most H-2Ld peptides. 
Interestingly, TAP also poorly transports peptides with this N-terminal motif, 
suggesting they are transported as N-terminally extended peptides, which are 
then customized by ERAAP (137). Furthermore, the presentation of Toxoplasma 
gondii derived HF10-H-2Ld epitope depends on proteolysis by ERAAP. 
Expansion of protective CTL populations was significantly impaired in infected 
ERAAP-deficient mice, which were more susceptible to toxoplasmosis compared 
to wild type counterparts (138).   
In addition to affecting class I expression, the assembled peptide-class I 
complexes in ERAAP-deficient cells have reduced cell surface half-life, thus 
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suggesting reduced stability (136). The presented class I-restricted peptides in 
ERAAP-deficient cells may display lower affinity for class I molecules, an effect 
similar to tapasin deficiency. Nevertheless, the quality of presented class I 
epitopes remains quite different, as demonstrated by Shastri and colleagues 
when comparing sequences of eluted class I epitopes from wild type and 
ERAAP-deficient cells (139). Thus, ERAAP-deficient cells present profoundly 
distinct peptide repertoire on class I molecules, as demonstrated by the ability of 
wild type CTL to recognize knockout APCs with the same activation level seen in 
the case of MHC-mismatched allogeneic cells. Conversely, ERAAP-deficient 
CTLs are also strongly activated when challenged with wild type APCs. This 
leads to the question whether N-terminally extended class I peptides are 
presented with a central ―bulge‖ which may lead to altered interaction with the T 
cell receptor (TCR) (140). Thus, ERAAP deficiency greatly affects the repertoire 
of peptides presented by class I molecules; this in turn leads to altered CTL 
responses.  
Human cells ubiquitously express ERAAP1, which is almost identical in 
function to mouse ERAAP. A second aminopeptidase, ERAAP2, which is ~51% 
identical to ERAAP1, is expressed in a tissue restricted manner. The two 
enzymes can form homodimers or heterodimers, which suggests that they may 
have non-overlapping functions and need to act concertedly during antigen 
processing. Human ERAAP1 prefers amino termini preceding large aliphatic 
residues such as leucine, whereas ERAAP2 prefers basic residues such as 
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arginine or lysine (141). The differential substrate specificity suggests that they 
generate a wide range of class I-restricted epitopes.  
ERAAP-deficient mouse DCs showed defective in vitro class I-restricted 
OVA peptide presentation by both direct and cross-presentation. ERAAP-
deficient DCs have enhanced response to Lymphocytic Choriomeningitis Virus 
(LCMV) gp33-derived class I peptide in vitro, suggesting that ERAAP degrades 
this epitope (136). At the same time, ERAAP negatively affects the 
immunorecessive influenza virus NP396-404 class I-restricted epitope, and has only 
a minor effect on gp33-derived class I epitope in in vivo studies (142). Van 
Endert and colleagues demonstrated that ERAAP1 and 2 in humans affect N-
terminal trimming of human immunodeficiency virus type-1 (HIV-1) p17 and p24 
derived class I-restricted precursor epitopes based on their length and internal 
peptide composition (143). 
ERAAP affects presentation of peptides displayed by non-classical class I 
molecules as well. Qa-2 molecules present a diverse set of nonameric peptides 
with an invariant histidine residue at position 7 in a TAP-dependent manner 
(136). Qa-2 has 30% reduced cell surface expression in ERAAP-deficient cells. 
On the other hand, Qa-1b specific CTL clones demonstrated slightly decreased 
activity against ERAAP-deficient cells (136). Therefore, ERAAP affects 
processing of class Ib-restricted peptides.  
ERAAP poorly trims peptides of 8—9 residues in length. Preferred 
substrates are 9—16 amino acid residues long peptides, while shorter or longer 
peptides are poorly trimmed. Interestingly, ERAAP‘s enzymatic activity is normal 
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in the absence of class I molecules, however, in that case, its action leads to 
preferential destruction of peptides found in the ER. Thus, ERAAP trims N-
terminally extended peptides and its action is dictated by peptide binding motifs 
of specific class I molecules. In sum, ERAAP works in synergy with class I 
molecules to facilitate generation of optimal class I epitopes (144).  
Class I-restricted peptides from wild type and ERAAP-deficient cells were 
compared in order to determine differences in their sequences. This comparison 
between wild type and knockout class I-associated self-peptide repertoire has 
revealed differences in peptide sequences presented by the two cell types, thus 
confirming ERAAP‘s contribution to shaping class I associated peptide repertoire 
(139). These studies along with analyses of the binding kinetics of ERAAP-
specific class I epitopes may point to changes during thymic CTL selection. 
In sum, ERAAP affects a large number of TAP-imported peptides in the 
ER either by destroying them, trimming them to the appropriate size for loading 
onto classical and non-classical class I molecules, or not affecting them. ERAAP 
does not interact with the PLC or TAP, yet plays a significant regulatory role by 
affecting the quality of the peptide repertoire presented by class I molecules 
(134). 
Completely assembled p/class I complexes negotiate the Golgi apparatus 
on their way to the cell surface. From the cell surface, class I molecules are 
slowly internalized and shuttled to the early endosomal compartment for peptide 
exchange. Endosomal peptide exchange is now considered as a potential 
mechanism for cross-presentation of class I-restricted antigens.   
32 
 
Insulin-regulated aminopeptidase: a novel aminopeptidase involved 
in class I-restricted antigen processing 
It has been postulated that there are additional aminopeptidases involved in 
class I-restricted peptide customization. Recently, Van Endert and colleagues 
described insulin-regulated aminopeptidase (IRAP), a Rab14+ endosome-
resident protease in human DCs as a necessary protease for antigen cross-
presentation. Rab14+ endosomes are devoid of class II molecules and other 
lysosomal proteases, but rich in class I molecules and TAP. IRAP is a ubiquitous 
zinc-dependent aminopeptidase that is closely related to ERAAP1 and ERAAP2. 
These two classes of aminopeptidases are strictly found in distinct cellular 
compartments. IRAP activity is IFN-  dependent and has broader peptide 
specificity compared to its ER-resident counterpart. IRAP can trim N-terminally 
extended class I peptides within endosomes and thereby allow their loading onto 
recycling class I molecules. Furthermore, IRAP-deficient DCs have poor cross-
presentation capacity, suggesting that there are two non-redundant cross-
presentation pathways, one that requires ERAAP and the other requiring IRAP 
(145). 
In summary, the class I processing pathway begins within complex, 
multisubunit structures called proteasomes. Next, processed peptides critically 
depend on TAP import into the ER, where some peptides can be directly loaded 
on class I molecules, while others are either customized or completely destroyed 
by ERAAP. Antigens presented by class I molecules are not only of endogenous 
origin, but also from exogenously-derived microbial, tumour or alloantigens 
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through the process of cross-presentation. This process is of great importance 
for establishing CTL-mediated immunity to pathogens and alloantigens, and 
eradicating tumours. How components of the class I pathway participate in cross-
presentation is discussed in detail below.  
 
Cross-presentation mechanisms and their role in establishing CTL 
immunity 
In 1977 Bevan first reported that class I molecules present exogenous antigens 
to CTLs through a process termed cross-presentation (146). Initial observations 
led to the conclusion that foreign antigens readily gain access to components of 
the class I processing pathway. APCs survey all tissues for tumour, allogeneic 
and infected cells (12). Upon encountering them, or particulate antigens, APCs 
acquire such cells by phagocytosis or internalize antigens from the extracellular 
environment by endocytosis or pinocytosis, and travel to the local draining lymph 
node or the spleen to present antigens to CTL and TH cells through the process 
called cross- and indirect presentation, respectively (147).   
Cross-presentation is a process of great importance because it allows 
presentation of exogenous allogeneic, tumour and microbial antigens to CTL for 
an appraisal (12). Nevertheless, despite the progress in elucidating mechanisms 
of cross-presentation, there is still controversy regarding the details of the 
underlying mechanism(s) and which proposed mechanism(s) operate under 
physiological conditions. 
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Cross-presentation leads to extensive communication between class I and 
class II processing pathways, thus blurring previously established strict 
boundaries between them. Internalized antigens are destined to the lysosomes 
for processing and presentation by class II molecules or for terminal degradation 
(69, 148). Nonetheless, exogenous antigens derived from dead, or tumour cells 
can also seep into the cytoplasm and become substrates for the class I 
processing machinery (11). Under such conditions, components of the class I 
antigen processing pathway capture and process these antigens, thereby 
affecting the process of indirect presentation of these antigens by class II 
molecules to TH cells for an appraisal. It is of significance to understand the 
progress made regarding cross-presentation mechanism(s) in order to gain 
insight into it‘s practical effects on the processing of class II-restricted, 
cytoplasmic antigens from dead cells for indirect presentation. The ultimate 
question addressed in this thesis is how components of the class I pathway 
modulate TH cell responses.  
The first mechanism proposes that cross-presentation of soluble and 
particulate exogenous antigens occurs entirely within the endocytic compartment 
(149). Endosomes can serve as the compartment where endogenously derived 
class I peptides are exchanged with those of exogenous origin. Such reported 
antigens are derived from influenza virus and other exogenous particulate 
antigens (150-153). This process was dependent on the activity of the lysosomal 
protease cathepsin S, and was entirely independent of proteasomes and TAP 
(Figure 3) (154, 155). Additionally, disulfide bond rich HSV-1 and influenza virus  
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Figure 3. Mechanism of cross-presentation: components of the MHC class 
II pathway facilitate peptide exchange and the loading of MHC class I with 
antigenic peptide. Exogenous antigens are processed by GILT and cathepsin S 
within the endosomal compartment and resulting peptides are loaded onto 
recycling class I molecules and p/class I complexes egress to the cell surface. At 
the same time, maturing endosomes fuse with the lysosomes, where class II 
molecules are loaded with cognate peptides.  
Ag, antigen; CatS, cathepsin S; ER, endoplasmic reticulum; ERAAP, ER-
associated aminopeptidase associated with antigen processing; GILT, -
interferon-inducible lysosomal thiol reductase; Ly, lysosomes; MHC, major 
histocompatibility complex; pm, plasma membrane; TAP, transporter associated 
with antigen processing. Adapted from (69).  
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derived antigens required GILT, a component of the class II processing pathway. 
GILT reduces disulfide bonds, which is a prerequisite for efficient cross-
presentation (156, 157). It is not clear what the contribution of this pathway is to
the total pool of cross-presented antigens and whether lysosomal proteases can 
precisely mimic the functions of various components of the class I antigen 
processing and presentation pathway.  
The second proposed mechanism of cross-presentation suggests that 
macropinocytosed soluble antigens can escape from early endosomes in DCs, 
but not from those in M , thus gaining access to proteasomes and the TAP 
transporter (Figure 4) (158, 159). Furthermore, the fate of potential class I 
antigenic peptides may be influenced by ERAAP (142). 
Thus, cross-presentation of exogenous antigens requires escape of the 
source antigen from endosomes to the cytoplasm and subsequent access to 
components of the class I-restricted antigen processing pathway (160, 161). 
Cresswell and colleagues have further investigated this process and 
suggested a somewhat different mechanism for antigen trafficking and access to 
components of the class I processing pathway in the ER. Accordingly, soluble 
internalized antigens negotiate the Golgi apparatus and translocate by retrograde 
traffic to the lumen of the ER. Such antigens are then released into the cytosol by  
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Figure 4. Mechanism of cross-presentation: exogenous antigens escape 
into the cytoplasm, where they are degraded within proteasomes to 
peptides which are transported via TAP to the ER. Exogenous antigens seep 
into the cytoplasm from the endosomes where they are degraded within 
proteasomes and the resulting peptides are transported to the ER via TAP where 
they are customized by ERAAP. At the same time, exogenous antigens are 
delivered to the lysosomes where cathepsins mediate their degradation in a GILT 
dependent manner.  
Ag, antigen; CatS, cathepsin S; ER, endoplasmic reticulum; ERAAP, ER 
associated aminopeptidase associated with antigen processing; GILT, -
interferon-inducible lysosomal thiol reductase; GN, Golgi network; Ly, lysosomes; 
MHC, major histocompatibility complex; pm, plasma membrane; TAP, 
transported associated with antigen processing. Adapted from (149). 
  
 
38 
 
sec61 where they become targets for proteasomes and TAP (32, 162). When 
soluble US6 is added to immature DC cultures, it is internalized by 
macropinocytosis and leaves these vesicles to translocate to the lumen of the 
ER. This then allows US6 to bind the ER luminal segment of TAP, and blocks 
peptide import from the cytoplasm. As a result, class I cell surface expression is 
decreased (32, 163). The same mechanism has been demonstrated for 
exogenously added 2m, as it increased cell surface class I expression in 2m-
deficient DCs, but not M  (164). 
The drawback of this mechanism is that in DCs, macropinocytosed 
material is quickly targeted to the lysosomes for degradation. Therefore, antigen 
escape from endocytic vesicles remains somewhat controversial. However, how 
would endosomal cargo in DCs find its way into the cytoplasm? There are 
several proposed mechanisms, which will be discussed later. 
The above studies nonetheless strongly point to the escape of exogenous 
cargo from the early endosomes suggesting the potential for class II-restricted 
antigens to be indiscriminately shunted into the class I-restricted antigen 
processing pathway and possibly lost to cytosolic degradation. Therefore, 
understanding how potential class II antigens are diverted to the class I 
processing pathway, as well as which components critically affect this process is 
missing. A better understanding of which factors affect indirect presentation will 
provide insights into TH cell mediated immunity against microbes, tumours and 
allografts. 
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The third proposed mechanism of cross-presentation is the most 
controversial and has drawn substantial criticism and support. An intriguing line 
of evidence suggests close contact between the ER and newly formed 
phagosomes. The ER membrane directly contributes to the formation of 
phagosomes, thus shuttling components of the class I pathway to the newly 
formed organelle. This mechanism suggests that Sec61 from within the 
phagosomal membrane allows export of engulfed proteins to the cytoplasm for 
proteasomal degradation. The resulting peptides are then preferentially 
transported back to the phagosomes via TAP or directed to the ER for loading 
class I molecules (Figure 5) (165, 166). 
This mechanism of cross-presentation has several drawbacks which 
include in vivo significance of this mechanism. Other concerns are regarding the 
purity of phagosomes isolated by ultracentrifugation. Such phagosomes were 
shown to contain components of class I processing machinery due to possible 
contamination with the ER membrane (167). Also, very frequently the endo-
lysosomal membranes are disrupted due to the use of latex or similar beads 
owing to their large size (167).  
Grinstein and colleagues found that the existing endosomes greatly 
contribute to phagosomal membrane formation, with little-to-no contribution from 
the ER to these membranes. They demonstrated that the major source of 
phagosomes is the plasma membrane. This finding also depended on the size of 
the particle used in the experiments: 1—3 m particles do not involve ER 
membrane; however larger particles may disrupt the endosomes. However,  
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Figure 5. Mechanism of cross-presentation: Exogenous antigen is captured 
within endo/phagosomes containing ER membrane. Exogenous antigens are 
retrotransported via Sec61 to the cytoplasm where they become proteasomal 
substrates. Processed peptides are next imported via TAP to endo/phagosomes 
where class I molecules are loaded with antigenic peptide. p/class I complexes 
egress to the cell surface. At the same time, exogenous antigens may be 
shuttled to the lysosomal compartment for processing and loading onto class II 
molecules. 
Ag, antigen; CatS, cathepsin S; ER, endoplasmic reticulum; ERAAP, ER 
associated aminopeptidase associated with antigen processing; GILT, -
interferon-inducible lysosomal thiol reductase; Ly, lysosomes; MHC, major 
histocompatibility complex; pm, plasma membrane; TAP, transported associated 
with antigen processing. Adapted from (149). 
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Grinstein et al. have used non-antigen coated latex beads (inert particles), which 
are not substrates for cross-presentation and are not processed by the class I 
pathway (168). 
However controversial, the above mechanism may play a role during 
phagocytosis of dead and tumor cells by DCs because of their size. Interestingly, 
the third mechanism strongly supports extensive antigen escape from maturing 
phagosomes. Large phagocytosed antigens may allow for extensive donation of 
the ER membrane to maturing phagosomal vesicles. 
The fourth proposed mechanism of cross-presentation suggests that gap 
junctions between cells participate in antigen exchange between cells. Gap 
junctions represent channels which are normally present in multicellular 
organisms. They are composed of two hemichannels each consisting of six 
connexin molecules. Previous studies have demonstrated that this type of 
cellular interaction allows the exchange of ions, nutrients and second 
messengers. These channels are not energy dependent, and allow passive 
diffusion of molecules up to ~1800 Daltons. Connexin 43 (Cx43) is most broadly 
expressed in cells of the immune system, including certain types of DCs. 
Interestingly, tumour cells, as well as cells infected with HSV-2 or human 
papilloma virus 16 lose gap junctions, in part to evade the activation of the 
immune system. Cx43 overexpression in cell lines led to fluorescent peptide 
diffusion into the neighbouring cells (169-171).  
Numerous cytosolic peptidases mediate effective clearance of the majority 
of proteasomal products, thus preventing uninterrupted peptide exchange 
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between cells. So, gap junction mediated cross-presentation may be effective for 
high copy number peptides. Also, peptides within class I and class II pathways 
regularly require protection by binding to chaperones, namely heat shock 
proteins (HSPs) and CRT (163, 172, 173).  
Another proposed mechanism of cross-presentation suggests that cells 
release vesicles rich is class I and class II molecules called exosomes, which 
participate in antigen exchange between cells (174, 175). It is not clear how 
effective and predominant this process is in transferring antigens to other cells for 
CTL recognition and activation.  
The majority of cross-presentation mechanisms suggest that exogenous 
antigens readily become available for class I processing components, namely 
proteasomes and TAP, before they are loaded onto class I molecules (159). It is 
increasingly evident that CTL-mediated immunity extensively depends on cross-
presentation as a source of exogenous antigens. Thus, the question remains 
which intricate mechanism(s) facilitate antigen cross-presentation and which 
APCs predominantly and most efficiently mediate this process.  
 
How do APCs mediate cross-presentation? 
The nature of cross-presented antigens remains a critical unanswered question. 
The answer may shed light on factors that drive donation of antigen and may 
also pin point factors within recipient APCs that allow for antigen cross-
presentation. Depending on the experimental model, various groups have arrived 
at different conclusions. This may not be surprising as there may be more than 
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one form of donated antigen. Earlier studies suggested that the whole protein is 
donated (176-178). However more recent studies have suggested that either 
peptides alone, or stabilized in complex with HSPs are cross-presented. Class I 
epitopes, or N-terminally extended proteasomal products frequently bind to 
HSP90 and CRT to both prevent peptide degradation, and facilitate 
donation/transfer to the ER (179-184). Shastri and colleagues found that HSP90 
stabilizes peptides and prevents their degradation during cross-presentation 
(172). On the other hand, the majority of studies suggest that HSP70 facilitates 
indirect presentation of class II-restricted antigens (183). Thus, based on 
available data, HSP90, HSP70, CRT and possibly other chaperones prevent 
cytosolic peptidase-mediated degradation of antigens and serve as chaperones 
of such antigens.  
Another question is whether necrotic cells, apoptotic cells, or cells under 
stress that causes autophagy (or autophagic type of cell death), or all three 
types, donate cross-presented antigens. Medzhitov and colleagues have 
reported that apoptotic cells/bodies do not serve as a source of cross-presented 
antigen. However, their results are perhaps influenced by the experimental model 
and its inherent limitation, especially since their conclusions were based only on 
in vitro studies. Also, they used apoptotic bodies, which were triggered to 
undergo transformation six hours prior to being used in experiments. However, 
apoptotic cells at earlier time points were not examined, because, at earlier time 
points, the donated antigens may have escaped complete destruction (185). 
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In separate studies, apoptotic or dying cells were directly injected into 
mice to investigate their cross-presentation potential (186, 187). Recent reports 
also indicate that apoptotic cells have modified cholesterol crystals present in the 
plasma membrane, as well as other protein aggregates which are recognized by 
cytosolic pattern recognition receptors (PRRs) of neighbouring cells, DCs or M  
which results in the activation of inflammasomes, the result of which is the 
secretion of proinflammatory cytokines interleukin-1  (IL-1 ) and IL-18 (188-190). 
Also, dying cells may release exclusive intracellular molecules, such as uric acid 
and fibrinogen, which in turn act as Toll-like receptor (TLR) agonists (191). 
Inflammasome activation is dependent on the adaptor molecule MyD88. Thus, 
signalling through MyD88 greatly facilitates innate immune responses (192). 
Apoptotic cells also release ATP and UTP, which are sensed by the nucleotide 
receptors on the target cells, P2Y2 and P2X7 (193, 194). Some of the released 
dead cell products are also sensed by cell surface and endosomal TLRs resulting 
in the release of proinflammatory cytokines such as tumour necrosis factor-  
(TNF- ), IFN-  and IL-12. Cross-presentation can be triggered by necrotic cells 
which are inducers of the inflammatory cytokine IL-1  (12, 195).  
Necrotic cells also release urate and pyrophosphate crystals, which can 
trigger cytosolic PRRs called NOD-like receptors (NLRs) that are expressed by 
tissue M  and dendritic cells. Activation of NLRs could potentially affect innate 
immune responses in the case of dying cells (188).  
Both in vitro and in vivo studies suggest that CD8 +CD11chigh DC are the 
major APCs, which mediate antigen cross-presentation through two potential 
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mechanisms: (1) Peripheral DCs, viz., skin Langerhans cells arrive in the lymph 
node carrying antigen and donate it to CD8 + DCs. (2) CD8 + DCs survey 
peripheral tissues, and upon acquisition of foreign antigen, travel to local draining 
lymph node and spleen to present it to CTL. Although this is an unresolved issue, 
it is possible that both mechanisms play a role during cross-presentation (9). 
Other studies have implicated M  in cross-presentation and showed that 
this heterogeneous tissue-specific cell type can also significantly contribute to 
cross-presentation. Recently, CD169+ subcapsular M  from lymph nodes were 
demonstrated to participate in tumor-derived antigen presentation, suggesting 
that APCs other than DCs also have the potential to mediate antigen cross-
presentation (196).  
Many studies point to DCs as the most efficient APCs dedicated to cross-
presentation. However, it remains unclear which factors direct ingested material 
to the class I processing pathway, and which steer them to the class II pathway. 
One explanation for activating both CTL and TH cells may be that there are two 
distinct subtypes regulating differential T cell activation. Thus, splenic DCs may 
be divided into two main groups: (a) CD8 + DCs, which express high levels of 
the C-type lectin DEC205; and (b) CD8 - DCs, which stain positive for mouse 
dendritic cell inhibitory receptor-2 (DCIR-2). 
CD8 +DEC205+ DCs localize to the T cell zone, while CD8 -DCIR-2+ DCs 
reside in the red pulp and marginal zone of the spleen. When CD8 +DEC205+ 
DCs were pulsed with OVA, they were able to present the antigen to both 
peptide-specific CTL and TH cells. Nonetheless, the TH cell response was less 
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pronounced. On the other hand, CD8 -DCIR-2+ DCs preferentially presented 
antigen to TH cells, but not to CTLs. In sum, distinct DC subsets are essential to 
ensure optimal CTL and TH cell responses to antigen (197). 
 Another key issue regarding antigen cross-presentation pertains to the 
cellular factors that influence shuttling of the internalized cargo to specific cellular 
compartments. Recently, mannose-receptor (MR) containing endosomes were 
demonstrated to target exogenous antigens towards the class I processing 
pathway. CD8 + DCs and M  specifically express MR on the cell surface. These 
DCs and M  critically depend on MR for efficient cross-presentation of 
exogenous OVA to CTL. Nonetheless, MR-deficiency does not perturb TH cell 
activation. MR positive endosomes were shown to be Rab5 and early endosome 
antigen 1 (EEA1) positive, but negative for the late endosomal and lysosomal 
markers, Rab7 and LAMP-1 (198, 199).  
Other factors can also favour antigen shuttling toward the lysosomes in 
DCs and M . In the case of DCs, they mainly pinocytose antigens that are 
presented by class II molecules. On the other hand, M  may utilize other cell 
surface molecules such as scavenger receptors (SR) to direct extracellular cargo 
to lysosomes, as seen by Rab7 and LAMP-1 co-staining with such receptors 
(200). Therefore, within M , a balance between MR and SR may affect the final 
destination of internalized antigen. These results suggest a requirement for two 
types of receptors, MR and SR, to control exogenous cargo and its 
compartmentalization.  
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Some of the previously described mechanisms of cross-presentation 
suggest that in DCs, phagocytosed antigens must escape fusion with lysosomes 
in order to access the cytoplasm for efficient cross-presentation. However, the 
exact mechanism(s) of antigen escape remains unclear, even though multiple 
studies have suggested that phagosomal cargo readily seeps into the cytoplasm. 
One proposed explanation is that immature DCs express lower levels of 
lysosomal enzymes compared to M , suggesting that DCs may be specialized for 
antigen cross-presentation (69).  
The second possible explanation is that DC phagosomes maintain neutral 
pH for a longer time period (several hours) compared to the acidic pH of M  
phagosomes. Neutral pH is maintained by the assembly of NADPH oxidase 
complex 2 (NOX2). Phagosomal maturation involves activation of vacuolar 
ATPases, which pump H+ ions into the lumen, thus lowering phagosomal pH and 
allowing fusion with the lysosomes. NOX2 complex in DCs leads to ROS 
formation, which consumes available H+ ions, thus raising the pH value to 
neutral. Amigorena and colleagues have demonstrated that NOX2 plays a role in 
cross-presentation of soluble antigens in DC (201-203). Different phagosomes 
may have distinct routes of activation, as suggested for IRAP-containing 
endosomes which are devoid of class II and do not fuse with the lysosomes. 
Phagosomes of different professional APCs may contain different levels of 
vacuolar ATPases versus NOX2 components, thus allowing antigen shuttling 
toward the endolysosomal compartment for presentation by class II molecules, or 
antigen escape to the cytosol.  
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Thus, specific cell surface receptors (MR versus SR), or specific cell 
surface markers/receptors (DEC205 versus DCIR-2) might determine whether 
the antigen is presented by class I, class II, or both. Furthermore, within DCs, 
NOX2 activation aids in antigen escape to the class I pathway and limits antigen 
availability to the lysosomes. In sum, there are numerous factors which regulate 
how and whether endocytosed antigens will be directed to the class I pathway 
and cross-presented to CTL for an appraisal. 
 
Minor histocompatibility antigens 
 
The critical role of minor HAgs in transplant outcome has been known since the 
advent of human leukocyte antigen (HLA) typing and HLA-identical sibling bone 
marrow transplantation. Herein, graft-versus-host disease (GVHD) fatalities occur 
even among those who received grafts from an identical twin. Allograft rejection 
and GVHD caused by minor histoincompatibility are complex genetic diseases 
(204). Humans differ from each other by ~0.1%, which is about 3 million sites 
across the 3 billion-nucleotide genomic landscape, caused by single nucleotide 
polymorphisms, short tandem repeats and copy number variations (205, 206). 
This is also true for monozygotic twins who were once considered genetically 
identical (207-209). Several mechanisms underlie these genetic differences, 
including somatic mutations in utero during development, meiotic and mitotic 
recombination and biased gene conversion (207, 210). Thus, genes and 
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genomes are constantly evolving, which in part explains how minor 
histoincompatibility arises in HLA identical transplants.  
 
MHC class I and class II-restricted murine minor HAgs 
The ideal setting for solid organ transplantation as well as bone marrow 
transfusion is when donor and recipient are MHC matched, or at least partially 
matched. However, even under conditions of full MHC compatibility, GVHD 
ensues, and it often requires life-long immunosuppressive treatments (211, 212). 
Such treatment leaves the patient vulnerable to dire side effects of medication, 
and most importantly, to increased risk of infections and development of invasive 
cancers (213). 
GVHD develops in MHC identical pairs as a result of subtle differences in 
self-proteins between donor and recipient. They stem from altered amino acid 
sequences, or as a result of gene silencing, thus lack of protein expression within 
the recipient. These donor-recipient differences often (but not always) result in 
MHC molecules presenting allogeneic peptides called minor HAgs. Class I- and 
class II-restricted minor HAgs result from subtle alterations of self-peptide 
sequences, or they are epitopes originating from proteins with differential 
expression, thus being recognized as non-self in the recipient (214). 
A summary of the major murine class I-restricted minor HAgs, with the 
donor representing 129- or C.B10-H2b-background (variant B) and the recipient 
C57BL/6-background (variant A) is presented in Table 1. The summary of murine 
class II-restricted minor HAgs reveals that very few have been described so far 
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(Table 2). The lack of information regarding class II-restricted minor HAgs 
precludes complete understanding regarding the ensuing TH response and its 
role in GVHD. 
 
Human HY minor HAgs and their impact on GVHD and organ 
transplantation 
There are many HLA class I- and class II-restricted minor HAgs that are encoded 
by genes residing within the Y chromosome. The list of human HLA class I and 
class II-restricted Y chromosome-encoded mHAgs reveals that the majority are 
encoded by genes orthologous to the murine counterparts (Table 3). Relatively 
little is known about other HLA class II-restricted minor HAgs.  
Recent studies have shown that HY minor HAgs have significant impact 
on the outcome of corneal tissue allografts. Minor HAg-specific CTL clones were 
isolated from the recipients. Recent studies on cornea transplant recipients 
indicate that mismatching for the minor HAg HLA-A1/HY promotes cornea 
rejection (204, 215).  
In stem cell transplantation recipients, the most immunodominant non-HY 
minor HAg is HLA-HA-1, whereas HY minor HAgs promote lesser immune 
response (216).  
Kidney transplants are very frequent in patients where haemodialysis 
becomes insufficient for toxin and waste metabolite removal. It was reported that 
there was reduced renal graft survival in the HLA-A2 group compared to other 
HLA class I recipients in gender-mismatched renal transplant pairs, indicating a 
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role for HLA-A2/HY minor HAg in the allograft outcome. These mismatches in 
minor HAgs might induce activation of CTL and TH effector cells, which ultimately 
lead to the destruction of the kidney epithelium (204). 
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Table 1. Major histocompatibility complex class I-restricted murine minor histocompatibility alloantigens 
Gene Minor 
HAg/MHC 
restriction 
Variant   
A                     
Variant         
B 
Cause(s) of 
incompati-
bility 
Tissue 
distribution 
Protein function Refer-
ence 
Mouse (H2) 
H60  H60/Kb / LTFNYRNL gene 
silencing 
leukocytes non-classical class I 
molecule 
(217) 
Emp3  H4/Kb SGTVYIHL pSGIVYIHL P12, P3 
variation 
leukocytes and 
epithelial cells 
cell adhesion (218) 
H28   H28/Kb nd FILENFPRL induced DCs and M  unknown function 
 
(219) 
Zfp106     H3a/Kb ASPCNSTVL TSPRNSTVL P1, P4 
variation 
ubiquitous nuclear protein (220) 
Stt3  H7/Db KAPDNRETL KAPDNRDTL P7 variation ubiquitous glycosylation in the 
ER 
(221) 
H13  H13/Db SSVVGVWYL SSVIGVWYL P4 variation leukocytes unknown function (222) 
H47  H47/Db SCILLYIVI SCILLYFVI1 P7 variation ubiquitous degradation of 
misfolded proteins 
(223) 
Uty  HY/Db WMHHNMDLI WMHHTVDLL male 
antigen 
ubiquitous  histone 
demethylase 
(224) 
Smcy  HY/Db nd KCSRNRQYL male 
antigen 
ubiquitous lysine demethylase (225) 
Smcy  HY/Dk nd RRLRKTLL male 
antigen 
ubiquitous lysine demethylase  (226) 
Smcy  HY/Kk GEGTGNMP TENSGKDI male 
antigen 
ubiquitous lysine demethylase (227) 
minor HAgs, minor histocompatibility alloantigens; P, position in the amino acid sequence of the peptide; P : carboxy-terminus of 
the peptide; nd: no described allele; bold italics: anchor residues; bold underlined: amino acid variation between allelic variants; 
1unknown whether presented; 2phosphorylated in variant B. Adapted from (3) 
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Table 2. Major histocompatibility complex class II-restricted murine minor histocompatibility alloantigens 
Gene Minor 
HAg/MHC 
restriction 
Variant   
A                     
Variant        
B 
Cause(s) 
of 
incompat-
ibility 
Tissue 
distribution 
Protein function Refer-
ence 
Mouse (H2) 
Il4i  H46/Ab HA[FVEAIPEL
QG]HV 
HM[FVEAIPE
LQG]HV 
P-1 
variation 
IL-4 induced in 
B cells and 
DCs 
flavin monoxidase (228) 
Rbp1  H3b/Ab np np  np np gene translation / 
DBY   HY/Ab NAG[FNSNRA
NSS]RSS 
SSS[FSSSRA
SSS]RSG 
P2, P4 
variation 
ubiquitous RNA helicase 
 
(229) 
DBY     HY/Ek REEA[LHQFR
SGRK]PI 
REEA[LHQFR
SGKS]PI 
P8, P9 
variation 
ubiquitous RNA helicase (229) 
minor HAgs, minor histocompatibility alloantigens; P, position in the amino acid sequence of the peptide; P : carboxy-
terminus of the peptide; np: not published; bold italics: anchor residues; bold underlined: amino acid variation between 
allelic variants; bracket: core epitope. Adapted from (3) 
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Table 3. Human major histocompatibility complex class I and class II-restricted HY minor histocompatibility alloantigens 
Gene Minor 
HAg/MHC 
restriction 
Variant   
A                     
Variant         
B 
Cause(s) of 
incompatibility 
Tissue 
distribution 
Protein function Refer-
ence 
Human (HLA) class I-restricted 
 
Smcy B 0702 SPSVDKARAEL SPSVDKAQAEL P8 variation ubiquious lysine 
demethylase 
(230) 
Smcy A 0201 nd FIDSYICQV male antigen ubiquious lysine 
demethylase 
(231) 
Usp9y  A 0101 IVDCLTEMY IVDSLTEMY P4 variation ubiquious ubiquitin specific 
peptidase 9 
 
(232) 
Uty    B 0801 LPHNHTDL LPHNRTDL P5 variation ubiquitous histone 
demethylase 
(233) 
Uty 
 
B 6001 
 
RESEEESVSL GESEEASPSL P7 variation ubiquitous histone 
demethylase 
(234) 
Rps4y1 B 5201 TIRYPDPVI TIRYPDPLI P8 variation ubiquitous ribosomal protein 
S4 
(235) 
Tmsb4y A 3303 
 
nd EVLLRPGLHFR male antigen ubiquitous thymosin beta 4 (236) 
Human (HLA) class II-restricted 
Dby DQ5 P[HIESFSDIVEG
E] 
P[HIENFSDIDMGE] P4, P9, P10 
variation 
ubiquitous RNA helicase (237) 
Dby DRB1 1501 ASTASKGRYIPP
HLRNKEA 
GSTASKGRYIPPHL
RNREA 
not known ubiquitous RNA helicase  (238) 
Rps4y1 DRB3 0301  LIKVNDTIQI VIKVNDTVQI P1, P8 variation ubiquitous ribosomal protein 
S4 
(239) 
minor HAgs, minor histocompatibility alloantigens; P, position in the amino acid sequence of the peptide; P : carboxy-terminus of the 
peptide; nd: no described allele; bold italics: anchor residues; bold underlined: amino acid variation between allelic variants; 
bracket: core epitope. Adapted from (3)   
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Furthermore, HY-specific CTLs have been detected in a female recipient 
who received a kidney from her HLA-identical brother (204). Allograft survival 
was significantly reduced in female recipients transplanted with male organs. 
This increased graft loss was seen after one year and between two and ten 
years, implying that HY incompatibility plays a significant role in renal allograft 
outcome in both acute and chronic rejection (204).  
Recent studies have suggested that beside T cell mediated responses in 
GVHD, there were antibody responses detected in male recipients when females 
were donors. These antibodies were directed against proteins encoded for by 
genes located in the Y chromosome that give rise to minor HAgs. These 
antibodies are associated with chronic GVHD (240). The human DBY protein 
causes both B and T cell responses (238, 241). Nonetheless, the presence of 
antibodies directed against RPS4Y1, another protein encoded by a gene located 
in the Y chromosome, and/or DBY are/is detected in female recipients 
transplanted with male allografts, which correlated with acute rejection (242, 
243). However, it is still not known what role, if any the antibody responses to 
DBY play in GVHD. 
 
Functional outcomes of TH1 cell responses  
 
TH1 activity is exerted for the induction and maintenance of CTL in addition to 
other immune cells (244, 245). Moreover, TH1 cells can also possess cytotoxic 
ability to directly kill infected and tumour cells (245). Taken together, the 
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evidence indicates that effective TH cell help, or direct effector action is essential 
for anti-infection or anti-cancer immunity (245). 
It is generally thought that the secondary, but not primary CTL responses 
depend on TH cell help (246). However, there are reported examples that TH cells 
exert their function in both cases, as discussed below. There are two major ways 
that TH cells assist CTL responses: one, with the help of DCs, through the 
process described as ―DC licensing‖, and two, directly, through cytokine 
secretion (246, 247). 
The DC licensing mechanism is considered more significant than the 
cytokine boost model. This model depends on CD40L expressed on TH cells that 
interacts with CD40 on DCs (248). Upon interaction between the two cells, a 
series of intracellular events leads to an increase in DC-mediated IL-12 and IL-15 
secretion that is followed by upregulation of costimulatory molecules. The 
resulting licensed DCs can effectively stimulate antigen-specific CTL expansion 
(247, 248).  
This model also demonstrated that TH cells and CTL do not need to be in 
direct contact with DC at the same time, because in vivo this type of random and 
complex interaction potentially could be difficult to achieve and maintain all the 
time during the induction of an adaptive immune response (249). The proposed 
model suggests that DCs capture antigen from necrotic or apoptotic cells, 
process the antigen for class II-restricted presentation to TH cells. Upon 
activation, TH cells upregulate CD40L and, through interaction with CD40, 
activate or license DCs to stimulate the response of naïve CTL that recognize 
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processed, class I-restricted antigen on the DCs (248). Thus, ―educated‖ DCs 
efficiently provide costimulatory signals to CTL (249). According to this model, 
the encounter of naïve CTL with antigen on the surface of resting DCs in the 
absence of TH cell help would not lead to priming, but to CTL tolerance. It is still 
not clear which factors favour CTL tolerance versus activation (250). 
However, there is still some controversy why some primary CTL 
responses are entirely dependent on help, whereas others are not, and whether 
CTL responses may be independent of any provided help (250). In contrast to 
the clear requirement for CD4 T cell help in generating a measurable primary 
CTL response to non-inflammatory and allogeneic antigens, a strong primary 
CTL response against many infectious agents can be readily measured in 
animals that lack TH cells. APCs are directly activated by the infectious agents 
that harbour or release TLR ligands. TLR activation then stimulates the APC to 
produce inflammatory signals, such as TNF-  or type 1 interferons (250, 251).  
However, secondary CTL responses to microbes are either completely 
absent or severely diminished by the absence of CD4 T cell help during the 
primary response (252). The un-helped memory CTL divid poorly, made less 
IFN-  and are unable to provide complete protection against the pathogen (253). 
Therefore, TH cells are essential for generating long-lived, functional CTL 
memory responses, which can be easily triggered upon re-exposure to the same 
pathogen (254).  
Independent studies have demonstrated that secondary CTL responses 
against tumour antigens also critically depend on TH cell programming during 
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initial encounter with antigen. In the case of tumour and microbial antigens, T cell 
help is indispensable for effective memory CTL responses (254). 
In contrast to agents that stimulate an inflammatory response, those that 
are generally non-infectious and, hence, non-inflammatory, require CD4 T cell 
help to generate a primary CTL response (255). Depending on the experimental 
model, the primary CTL response against soluble antigens as well as cellular 
non-infectious agents may be the best understood. For example, the primary in 
vivo CTL response to syngeneic spleen cells loaded with OVA requires TH cell 
help (256). 
An alternative model for T cell help predicates derived cytokines such as 
IL-2 and IFN-  in CTL activation and differentiation. IL-2 is one of the few effector 
cytokines made by naive TH cells, and is secreted for a relatively short period 
immediately after activation (252, 257). It is possible that IL-2 contributes to 
stabilization of CD40L expression in vivo, as recently suggested (258). 
 
Summary and Unanswered Questions 
Mechanisms of cross-presentation suggest extensive communication 
between class I and class II antigen processing pathways. During cross-
presentation, exogenous antigens escape into the cytosol and become 
substrates for the class I processing pathway (12). However, some of these 
studies were limited only to model antigens and only examined presentation of 
overexpressed antigens (259).  
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The mechanisms of cross-presentation all favour shuttling of dead cell 
material or particulate antigens from phagosomes or endosomes to the 
cytoplasm where such antigens become exposed to components of the class I 
processing pathway (259). In this way, it may be proposed that dead cell or 
particulate antigens become limiting for lysosomal loading of antigenic peptides 
onto class II molecules. 
Very few studies if any have defined the rules and factors governing 
indirect presentation of cytoplasmic antigens onto class II molecules (260). There 
are no data available that address the specific roles of the proteasomes, TAP 
and ERAAP on indirect presentation of cytoplasmic antigens. Furthermore, there 
is a significant lack of information regarding indirect presentation of cytoplasmic 
self, tumour or bacterial antigens.   
Several cytoplasmic class II-restricted epitopes are dependent on 
proteasomes, and independent of autophagy (87, 260). Therefore, proteasomes 
could affect the resulting TH cell TCR repertoire; however these changes were 
not addressed in previous research efforts. 
It is not known whether TAP has any effect on indirect presentation of 
class II-restricted epitopes. Also, it is not known how TAP-deficiency may affect 
the TH cell TCR repertoire. Current evidence based on serologic typing of select 
TCR beta-chains suggests that the TCR repertoire of TAP-null TH cells is very 
similar to that of wild type TH cells (261). However, it remains to be determined 
whether the CDR3 loops of the TCR alpha and beta chains are similar between 
the wild type and TAP-deficient TH cells. Some class II epitopes are both 
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produced by proteasomes and transported by TAP into the endosomes (87). 
These distinct class II epitopes are presented by thymic epithelium and DCs and 
affect the process of thymic selection that would be predicted to result in changes 
in the TH cell TCR repertoire. Therefore, it is of import to define the resulting TH 
cell TCR repertoire in order to gain insight into the impact of the changes in the 
class I antigen processing pathway on peripheral TH cell responses.   
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CHAPTER II 
 
PROTEASOMES, TAP AND ERAAP CONTROL CD4+ TH CELL RESPONSES 
BY REGULATING INDIRECT PRESENTATION OF MHC CLASS II-
RESTRICTED CYTOPLASMIC ANTIGENS 
 
Introduction 
Cytoplasmic antigens derived from viruses, cytosolic bacteria, tumours and 
allografts are presented to T cells by MHC class I or class II molecules. In the 
case of class II-restricted antigens, professional APCs acquire antigens during 
uptake of dead, class II-negative cells and present them via a process called 
indirect presentation. 
It is generally assumed that the cytosolic, or class I-processing machinery—
which supplies peptides for presentation by class I molecules—plays very little 
role in indirect presentation of class II-restricted, cytoplasmic antigens. 
Remarkably, upon testing this assumption, we found that proteasomes, TAP and 
ERAAP, but not tapasin, partially destroyed or removed cytoplasmic, class II-
restricted antigens such that their inhibition or deficiency led to dramatically 
increased TH cell responses to cytosolic allograft (HY) and microbial (Listeria 
monocytogenes) antigens. In another set of experiments, we uncovered novel 
class II-restricted self-epitopes from TAP- and ERAAP-deficient APCs, which 
were absent from wild type cells. Such novel TAP- and ERAAP-knockout class II 
epitopes were found upon testing a panel of peptides derived from SV40 large T 
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antigen. From these findings, and the altered repertoire of class II-restricted self-
peptides presented by wild type, TAP- and ERAAP-deficient cells, a novel model 
emerged in which the class I-processing machinery regulates the quantity, as 
well as quality of cytoplasmic peptides available for presentation by class II 
molecules, and hence modulates TH cell responses, as well as the TH T cell 
receptor repertoire.  
Results 
 
Indirect presentation of HY alloantigen primes TH cells in vivo 
In order to study the mechanism(s) underlying indirect presentation of cytosolic 
MHC class II-restricted antigens, we first determined how the male H2Ab-
restricted HY minor HAg is presented to TH cells. The alloantigenic HY peptide 
(pHY) is derived from RNA helicase, a ubiquitously expressed nucleo-
cytoplasmic protein encoded by the evolutionarily conserved Dby gene located 
on the Y-chromosome (13, 229). No other H2b-restricted T cell epitopes are 
derived from this helicase (262). Thus, female C57BL/6 (B6) and B6.129-Ab-/- 
mice were immunized with H2b-compatible but mHAg-incompatible (Table 5) 
male 129 donor splenocytes. After 7d, the ability of mHAg-reactive TH cells and 
CTL to produce IFN-  was determined by ELISpot assay.  
 Immunisation of B6 mice resulted in IFN- -producing splenic TH cells to 
pHY but not to the control Dbx-encoded self HX peptide (pHX; Figure 6) 
expressed by both males and females. This response was specific because pHY 
did not elicit any IFN-  response from immune B6.129-Ab-/- mice (Figure 6). 
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Moreover, female B6 mice immunized with male 129-Ab-/- splenocytes also 
primed pHY-reactive TH cells (Figure 6). Therefore, we conclude that the H2Ab-
restricted HY antigen is indirectly presented to TH cells in vivo.  
 In the same experiment described above, the role of pHY-specific TH 
response in eliciting CTL responses to class I-restricted mHAgs was determined. 
We found IFN- -producing CTL responses to the immunodominant H2Kb-
restricted, H60 and H4b alloantigens but not to control H2Kb-restricted, SV40 T-
Ag (TAg) epitope-IV (epi-IV) in B6 mice immunized with either male 129 or 129-
Ab-/- splenocytes (Figure 6). Nonetheless, B6.129-Ab-/- recipients did not elicit CTL 
responses to class I-restricted pH60 and pH4b (Figure 7a). Furthermore, TH and 
CTL responses were similar to those described above using Ii-deficient recipients 
(Figure 8). Recipient B6.129-Ii-/- mice immunized with 129 splenocytes did not 
elicit any TH response to HY alloantigen. CTL response to the H2K
b-restricted, 
H60 and H4b alloantigens, akin to B6.129-Ab-/- recipients, was lost (Figure 8). 
These data together suggest that the primary CTL response to mHAgs is entirely 
dependent on CD4 T cell help. 
 
Indirect presentation of pHY requires CD8 + dendritic cells 
Because Dby is broadly expressed (263), it was important to determine which 
donor cell type donates and which recipient APC type presents the alloantigen. 
For this, we took advantage of the hDTRtg mouse–in which the human DT 
receptor transgene expression is regulated by the Cd11c enhancer/promotor  
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Figure 6. Indirect presentation of the male HY alloantigen. B6 and B6.129-Ab-
/- female mice were immunised with either male donor 129/SvJ or 129-Ab-/- 
splenocytes. After 7d, IFN-  response by TH cells to pHY/Ab or negative control 
pHX/Ab was assessed by ex vivo ELISpot assay. At the same time, IFN-  
response by CTL to pH60/Kb, pH4b/Kb and negative control SV40 epi IV/Kb was 
similarly determined. Data represent 6 similar experiments using ~4 recipient 
mice per group per experiment; ±sem (standard error of mean). 
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Figure 7. Cross-presented class I-restricted H60 and H4b alloantigens 
require CD4+ T cell help. (a) B6 and B6.129-Ab-/- female mice were immunised 
with either male donor 129/SvJ or 129-Ab-/- splenocytes. After 7d, IFN  response 
by CTL to pH60/Kb, pH4b/Kb and negative control SV40 epi IV/Kb was assessed 
by ex vivo ELISpot assay. Data represent 6 similar experiments using ~4 
recipient mice per group per experiment; ±sem (standard error of mean). (b) 
Female B6 and B6.129-TAP-/- female mice were immunized with male donor 
C.B10-H2b (BALB.B) or B.129-TAP-/- splenocytes. Seven days later, IFN-  
response by CTL to p60/Kb, pH4b/Kb and SV40 epi-IV/Kb was determined by ex 
vivo ELIspot assay. Data represent 8 similar experiments using ~2—3 recipient  
mice per group per experiment; ± sem. (c) Female B6, B6.129 CD8 -/- and 
B6.129-TAP-/- mice were immunized with male donor B.129-TAP-/- splenocytes. 
Seven days later, IFN-  response by CTL to p60/Kb, pH4b/Kb, and SV40 epi-IV/Kb  
was determined by ex vivo ELIspot assay. Data represents 4 similar experiments 
using ~3 recipient mice per group per experiment; ±sem. (d) Female B6 and 
B6.129-TAP-/- mice were immunized with male donor B.129-TAP-/- splenocytes, 
while B6.129- 2m-/- female mice were immunized with male donor B.129-TAP-/- 
splenocytes. IFN-  response by CTL to p60/Kb, pH4b/Kb, and SV40 epi-IV/Kb  was 
assessed 7 days later as above. Data represents 3 similar experiments using ~3 
recipient mice per group per experiment; ±sem. 
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Figure 8. Cross-presented class I-restricted H60 and H4b alloantigens 
require CD4+ T cell help. Female B6 and B6.129-Ii-/- female mice were 
immunized with male donor 129/SvJ splenocytes. Seven days later, IFN-  
response by TH cells to pHY/A
b and to pHX/Ab and   by CTL to p60/Kb, pH4b/Kb, 
and SV40 epi-IV/Kb was determined as above. Data represent 3 similar 
experiments using ~3 recipient mice per group per experiment; ±sem 
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(264). Thus, DT administration renders hDTRtg mice conditionally deficient in 
CD11c+ myeloid cells including DCs and splenic sub-capsular macrophages 
(264, 265). We previously reported that DT-treated B6.FVB-hDTRtg mice became 
DC-deficient within ~18hrs and remained so for 72hrs (266).  
To determine which APC type presents donor mHAg, we treated B6.FVB-
hDTRtg mice with PBS or DT and immunized them ~18 hrs later with male 
splenocytes from 129.FVB-hDTRtg mice that received PBS ~18 hrs earlier. 
On d7, pHY-specific TH cell responses were monitored. Depletion of 
recipients‘ CD11c+ cells dramatically tempered TH cell responses to pHY 
compared to that observed in mice containing CD11c+ cells (Figure 9a). Similarly, 
depletion of donor CD11c+ cells resulted in poor TH cell responses to pHY 
(Figure 9b) indicating a significant role for CD11c+ cells in donating alloantigens 
for indirect presentation. As expected, depletion of both recipient and donor 
CD11c+ cells resulted in no TH cell response to pHY (Figure 9a). 
 Additional data revealed that both donor and recipient CD11c+ cells were 
required to mediate cross-presentation of class I-restricted pH60 and pH4b in vivo 
(Figure 10). Depletion of recipient, and both recipient and donor CD11c+ cells 
greatly tempered CTL responses to class I-restricted H60 and H4b (Figure 10a). 
Depletion of donor CD11c+ cells reduced the CTL response to half of the wild 
type response to H60 and H4b (Figure 10b). Because DCs express high levels of 
CD11c, constitute the majority of CD11c+ splenocytes and are critical for priming 
naïve T cells, the above data suggest that DCs are responsible for indirect 
presentation.     
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Figure 9. Indirect presentation of the class II-restricted HY alloantigen 
requires CD8 + DCs. (a) Female recipient B6.FVB-hDTRtg mice treated with 
vehicle (PBS) or DT and immunised 24 hrs later with male donor 129.FVB-
hDTRtg splenocytes from mice that were either PBS- or DT-treated 24 hrs earlier. 
After 7d, IFN-  response by TH cells to pHY/Ab or negative control pHX/Ab was 
assessed by ex vivo ELISpot assay. Data represent 6 similar experiments using 
~3 recipient mice per group per experiment; ± sem. (b) Male donor 129.FVB-
hDTRtg mice treated with vehicle or DT and used 24 hrs later to immunise female 
B6.FVB-hDTRtg mice. After 7d, IFN-  response by TH cells to pHY/Ab and pHX/Ab 
was determined by ex vivo ELISpot assay. Data represent 6 similar experiments 
using ~3 recipient mice per group per experiment; ± sem. (c) 129/SvJ and 129-
Batf3-/- female recipients were immunized with male C57BL/6 donor splenocytes. 
After 7d, IFN-  response by TH cells to pHY/Ab and pHX/Ab was determined by 
ex vivo ELIspot assay. Data represents 2 similar experiments using ~2—4 
recipient per group per experiment; ± sem. (d) B6 female recipients were 
immunized with male 129/SvJ or 129-Batf3-/- donor splenocytes. After 7d, IFN-  
response by TH cells to pHY/Ab and pHX/Ab was determined by ex vivo ELIspot 
assay. Data represents 2 similar experiments using ~2—4 recipient per group per 
experiment; ± sem. (e) 129/SvJ and 129-Batf3-/- female recipients were 
immunized with either male 129/SvJ or 129-Batf3-/- donor splenocytes. After 7d, 
IFN-  response by TH cells to pHY/Ab and pHX/Ab was determined by ex vivo 
ELIspot assay. Data represents 2 similar experiments using ~2—4 recipient per 
group per experiment; ± sem.   
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Figure 10. Cross-presentation of the class I-restricted H60 and H4b 
alloantigens depends on CD8 + DCs. (a) Female recipient B6.FVB-hDTRtg 
mice treated with vehicle (PBS) or DT and immunised 24 hrs later with male 
donor 129.FVB-hDTRtg splenocytes from mice that were either PBS- or DT-
treated 24 hrs earlier. After 7 days, IFN  response by CTL cells to p60/Kb, 
pH4b/Kb, and SV40 epi-IV/Kb was determined by ex vivo ELISpot assay. Data 
represent 6 similar experiments using ~2 recipient mice per group per 
experiment; ± sem. (b) Male donor 129.FVB-hDTRtg mice treated with vehicle or 
DT and used 24 hrs later to immunise female B6.FVB-hDTRtg mice. After 7 days, 
IFN  response by CTL cells to p60/Kb, pH4b/Kb, and SV40 epi-IV/Kb was 
determined by ex vivo ELISpot assay. Data represent 6 similar experiments 
using ~3 recipient mice per group per experiment; ± sem. (c) 129/SvJ and 129-
Batf3-/- female recipients were immunized with male C57BL/6 donor splenocytes. 
7 days later, IFN-  response by CTL to pHY/Db, and SV40 epi-IV/Kb was 
determined by ex vivo ELIspot assay. Data represents 2 similar experiments 
using ~2—4 recipient per group per experiment; ± sem. (d) B6 female recipients 
were immunized with male 129/SvJ or 129-Batf3-/- donor splenocytes. 7 days 
later, IFN-  response by CTL to p60/Kb, and SV40 epi-IV/Kb was determined by 
ex vivo ELIspot assay. Data represents 2 similar experiments using ~2—4 
recipient per group per experiment; ± sem. (e) 129/SvJ and 129-Batf3-/- female 
recipients were immunized with either male 129/SvJ or 129-Batf3-/- donor 
splenocytes. 7 days later, IFN-  response by CTL to pHY/Db, and SV40 epi-IV/Kb  
was determined by ex vivo ELIspot assay. Data represents 2 similar experiments 
using ~2—4 recipient per group per experiment; ± sem. 
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To firm the contribution of DCs in indirect presentation and to determine 
which DC subset is responsible, we used the recently reported 129-Batf3-/- mice 
which are deficient in splenic CD8 + DCs (267). Female 129 and 129-Batf3-/- 
mice were immunized with male B6, 129 or 129-Batf3-/- splenocytes and the HY-
specific TH cell response was monitored 7d later. The data revealed that the lack 
of splenic CD8 + DCs in the recipient dramatically reduced the TH cell response 
to HY (Figure 9c). Similarly, the lack of donor CD8 + DCs resulted in much 
tempered TH cell response to HY (Figure 9d), which was completely lost upon 
immunising CD8 + DC-deficient female recipients with male donor splenocytes 
lacking CD8 + DCs (Figure 9e). We also monitored pH60-specific CTL 
responses in the experiment described above. The data revealed a requirement 
for donor and recipient CD8 + DCs in cross-priming CTL responses to pH60, 
pH4b and pHY (Figure 10c-e). Together, these data suggest that CD8 + DC play 
important roles in donating and indirectly presenting the HY alloantigen. 
Upon DC activation in recipient mice, these cells secrete many cytokines 
and upregulate activation markers. DC mainly upregulate CD40, CD80 and CD86 
as well as secrete IL-12, IL-2 and other cytokines. We sought to determine the 
role for IL-12 by immunizing B6 and B6.129-IL-12-/- mice with 129 donor 
splenocytes. The lack of IL-12 in recipients resulted in tempered TH responses to 
HY (Figure 11). Therefore, this cytokine plays a role in establishing full TH cell 
responses. 
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Figure 11. Recipient DC-derived IL-12 affects TH cell response to class II-
restricted HY alloantigen. Female B6 and B6.129-IL12-/- female mice were 
immunized with male donor 129/SvJ splenocytes. Seven days later, IFN-  
response by TH cells to pHY/A
b and to pHX/Ab was determined as above. Data 
represent 3 similar experiments using ~3 recipient mice per group per 
experiment; ±sem  
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TAP and ERAAP regulate TH cell responses to pHY 
Because pHY is derived from nucleo-cytoplasmic RNA helicase, we predicted 
that components of the class I processing machinery might have access to HY  
and potentially regulate its availability for indirect presentation. Therefore, we 
next determined whether TAP had any role in indirect presentation of pHY. 
Immunisation of female B6 mice with male splenocytes derived from H2b-
compatible but mHAg-incompatible C.B10-H2b (BALB.B; Table 5) or B.129-TAP-/- 
(B stands for BALB.B) mice generated comparable pHY-specific TH cell 
responses (Figure 12a, b). Similarly, B6.129-TAP-/- female mice immunised with 
C.B10-H2b male splenocytes elicited comparable pHY-specific TH cell responses 
(Figure 12a, b). Surprisingly, however, when B6.129-TAP-/- female recipients 
were immunised with B.129-TAP-/- male donor splenocytes, 2—3-fold increased 
TH cell response against H2Ab-restricted pHY was observed (Figure 12a). Thus, 
TAP function in both donor and recipient cells had a detrimental effect on the 
indirect presentation of class II-restricted cytoplasmic antigen that tempered the 
TH cell response. 
 We considered the possibility that peptides translocated by TAP into the 
ER might become substrates for destruction by ERAAP, and hence unavailable 
for presentation. To test this possibility, B6, B6.129-TAP-/- and B6.129-ERAAP-/- 
female mice were immunised with C.B10-H2b, B.129-TAP-/- or 129-ERAAP-/- 
male splenocytes. As with B6 and B6.129-TAP-/- mice, B6.129-ERAAP-/- female 
mice immunised with wild type male splenocytes elicited similar pHY-specific TH 
cell responses (Figure 12b—d). In striking contrast, immunisation of B6.129-  
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Figure 12. ERAAP and TAP impact indirect presentation of class II-
restricted HY alloantigen. (a) B6 and B6.129-TAP-/- female mice were 
immunised with either male donor C.B10-H2b or B.129-TAP-/- splenocytes. IFN-  
response by TH cells to pHY/Ab and pHX/Ab was determined by ex vivo ELISpot 
assay after 7d. Data represent 8 similar experiments using ~3—4 recipient mice 
per group per experiment; ±sem. (b) B6, B6.129-TAP-/- and B6.129-ERAAP-/- 
female mice were immunised with either male donor C.B10-H2b or B.129-TAP-/- 
splenocytes and IFN-  response by TH cells to pHY/Ab and pHX/Ab was 
assessed 7d later by ex vivo ELISpot assay. Data represent 7 similar 
experiments using ~4 recipient mice per group per experiment; ±sem. (c) B6, 
B6.129-TAP-/- and B6.129-ERAAP-/- female mice were immunised with either 
male donor 129S6/SvEvTac or 129-ERAAP-/- splenocytes. IFN-  response by TH 
cells to pHY/Ab and pHX/Ab was determined 7d later by ex vivo ELISpot assay. 
Data represent 7 similar experiments using ~2—3 recipient mice per group per 
mice; ±sem. (d) B6 and B6.129-ERAAP-/- female mice were immunized with male 
donor 129S6/SvEvTac or 129-ERAAP-/- splenocytes. After 7d, IFN-  response by 
TH cells to pHY/Ab and pHX/Ab was determined by ex vivo ELISpot assay. Data 
represent 3 similar experiments using ~2—3 recipient mice per group per 
experiment; ±sem. 
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ERAAP-/- female mice with B.129-TAP-/- male splenocytes resulted in two-fold 
increases of pHY-specific TH cell responses (Figure 12b). Similarly, immunisation 
of B6.129-TAP-/- or B6.129-ERAAP-/- mice with 129-ERAAP-/- male splenocytes 
resulted in a 2—3-fold increase in pHY-specific TH cell response (Figure 12c, d). 
As a control for the above experiments, monitoring of CTL response in 
wild type mice immunised with male wild type or TAP-deficient donor splenocytes 
revealed an identical CTL response to pH60 and pH4b, suggesting that the two 
class I-restricted mHAgs are cross-presented (Figure 7b). As expected, TAP-
deficient recipient mice did not respond to class I-restricted mHAgs as they are 
devoid of CD8+ T cells (Figure 7b). We, therefore, conclude that a pool of 
cytoplasmic class II-restricted antigens is pumped into the ER by TAP, thence 
destroyed by ERAAP in both donor and recipient cells.   
 
TAP and ERAAP regulate indirect presentation of class II-restricted 
bacterial antigens in vivo 
To determine the generality of TAP‘s and ERAAP‘s role in indirect antigen 
presentation, we tested whether the class I pathway impacts indirect presentation 
of L. monocytogenes-derived class II-restricted antigens. L. monocytogenes 
listerolysin O (LLO) disrupts the phagolysosome to permit entry of the organism 
into the cytoplasm for its growth, and multiplication. Therefore, the priming of TH 
cell responses against listerial antigens requires indirect presentation (83, 147, 
268). Thus, B6, B6.129-TAP-/-, B6.129-ERAAP-/- and B6.129-Ab-/- as well as 
129S6/SvEvTac, 129-ERAAP-/-, B6.129-Ab-/- and 129-Ab-/- mice were inoculated 
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i.p. with bacteria, boosted 14d later and secondary TH cell responses to known 
H2Ab-restricted epitopes were monitored after an additional 14d. PBS-treated B6 
and 129 mice served as negative controls.  
We observed a 2—5-fold increase in the secondary TH cell response to 
H2Ab-restricted pLLO(190-201), p60(177-188), pLLO(318-329), and pLLO(253-
264) in B6.129-TAP-/- mice compared to B6 mice (Figure 13a, b). A similar 
pattern of increased TH cell reactivity to pLLO(190-201), p60(177-188) and 
pLLO(318-329) was observed in ERAAP-deficient mice compared to B6 mice 
(Figure 13a, b).  
In contrast, the response to pLLO(253-264) was indistinguishable between 
wild type and ERAAP-deficient mice (Figure 13b). As expected, neither Listeria-
inoculated H2Ab-/- nor PBS-treated wild type mice responded to the four listerial 
peptides; none of the mice responded to irrelevant peptides (Figure 13). In 
additional experiments, we also found that the primary TH response to L. 
monocytogenes antigens—elicited by retro-orbital bacterial inoculation—yielded 
similar results as above (Figure 14). The primary TH cell response to H2Ab-
restricted pLLO(318-329), p60(177-188), and pLLO(253-264) in B.129-TAP-/- 
mice was greater in comparison to wild type mice (Figure 14). Also, the TH cell 
response to H2Ab-restricted pLLO(318-329), p60(177-188) in ERAAP-deficient 
mice was increased compared to wild type mice, except for pLLO(253-264) 
where, once again, there was no difference between 129 and 129-ERAAP-/- mice 
(Figure 14).  
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Figure 13. TAP and ERAAP regulate class II-restricted listerial antigen 
presentation. (a) B6, B6.129-TAP-/-, B6.129-ERAAP-/- or B6-129-Ab-/- mice were 
inoculated with L. monocytogenes or delivered PBS i.p. and boosted 2 weeks 
later. Two weeks after boost, immune splenocytes were stimulated with the 
indicated peptides for 48hrs and IFN-  response by TH cells was monitored by  
ELIspot assay. (b) 129S6/SvEvTac, B.129-TAP-/-, 129-ERAAP-/- or 129-Ab-/- mice 
were primed and boosted as in (a). Two weeks after boost, immune splenocytes 
were stimulated with the indicated peptides for 48hrs and IFN-  was monitored by 
ELIspot assay. Data represents 2 similar experiments using 3—4 mice/group; 
±sem. 
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Figure 14. TAP and ERAAP impact quantitative aspects of primary TH cell 
response to L. monocytogenes-derived class II-restricted epitopes. B6, 
B6.129-TAP-/- and B6.129-Ab-/- or 129S6/SvEvTac, 129-ERAAP-/-, and 129-Ab-/- 
mice were inoculated i.v. with ~5x104 cfu Lm or administered PBS. On d14, IFN-  
response by TH cells to pLLO(318-329), p60(177-188), pLLO(253-264) and pHX 
was assessed by ELIspot assay. Data represents 2 similar experiments using 
3—4 mice/group; ± sem.  
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Thus, the TAP and ERAAP effect on indirect presentation of cytoplasmic 
class II-restricted antigens appears to be a general principle as they impact TH 
cell responses to mHAgs and bacterial antigens similarly. 
 
Proteasomes regulate indirect presentation of HY mHAg 
Several mechanisms can potentially explain the above finding: (a) competition 
between class I and class II molecules for antigen; (b) competition between CD4+ 
and CD8+ T cells; (c) enhanced autophagy and/or enhanced ER-associated 
degradation (ERAD); and (d) quantitative differences in the antigen(s) presented.  
To test whether competition for antigen played a role, the TH response of 
female B6, B6.129- 2m-/- and B6.129-TPN-/- mice—which, akin to TAP 
deficiency, lack functional class I-assembly complex due to 2m and tapasin 
deficiency—was assessed after immunising with male C.B10-H2b or B.129-TAP-/- 
splenocytes. All three recipients elicited similar pHY-specific TH cell responses 
(Figure 15a), suggesting that simply lacking class I does not ‗free up‘ more 
cytoplasmic antigens for presentation by class II molecules. In conjunction with 
the fact that no known CTL epitopes are derived from Dby-encoded helicase 
(262), competition for antigen is a less likely explanation for our finding.    
To ascertain whether the increased TH cell responses was a compensatory 
effect caused by the absence of recipient CTL, B6.129-CD8 -/- female mice were 
immunised with either C.B10-H2b or B.129-TAP-/- male splenocytes. The resulting 
TH cell response to pHY was comparable in both wild type and CD8+ T cell-
deficient mice (Figure 15b). 
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As expected, female B6.129- 2m-/- and B6.129-CD8 -/- recipients did not 
mount any IFN-  response to class I-restricted mHAgs (Figure 7c, d). Hence, 
competition between CD4+ and CD8+ T cells is unlikely to explain the increased 
TH response in the absence of TAP or ERAAP.  
TAP and 2m deficiency enhances ERAD (269). ERAD can enhance 
autophagy (270), which is required for class II-restricted cytoplasmic antigen 
presentation (18, 20, 21, 25, 271). Nevertheless, we found that immunisation of 
female B6 mice with male 129 splenocytes treated with tunicamycin—which 
induces ERAD due to stress from accumulating unfolded proteins—completely 
abrogated the TH response to pHY whilst DMSO-treated donor cells responded 
as expected (Figure 15c). Similarly, induction of autophagy—by maintaining 
donor male splenocytes in nutrition-free conditions prior to immunisation of 
female B6 mice—did not enhance, but instead abrogated the TH response to 
pHY (Figure 15d). Additionally, constitutive autophagy was not enhanced in TAP-
/- (TAPTAg) or 2m-/- ( 2mTAg) TAg-SV40 large T antigen transformed fibroblast 
lines compared to similarly transformed wild type fibroblasts (wtTAg; (272) as 
similar levels of LC3-I and LC3-II were detected in immunoblots of proteins 
extracted from wild type and mutant lines (Figure 15e). Next, autophagy was 
inhibited in donor cells with the help of the pharmacological inhibitor 3-MA for ~4 
hours. Absence of autophagy in donor cells increased the TH cell response to HY 
alloantigen in recipients (Figure 16). Interestingly, the TH response was slightly 
increased compared to vehicle-treated donor cells, suggesting that reduced  
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Figure 15. Neither antigen competition, T cell competition, ERAD nor 
enhanced autophagy explain increased TH cell response to pHY in TAP-/- 
mice. (a) B6, B6.129-TPN-/- and B6.129- 2m-/- female mice were immunised with 
male donor B.129-TAP-/- splenocytes and IFN-  response by CD4 T cells to 
pHY/Ab and pHX/Ab was assessed 7d later by ex vivo ELIspot assay. Data 
represents 3 similar experiments using 27 recipient mice; ±sem. (b) B6 and 
B6.129-CD8 -/- female mice were immunised with either male donor C.B10-H2b, 
or B.129-TAP-/- splenocytes. IFN-  response by CD4 T cells to pHY/Ab and 
pHX/Ab was determined by ex vivo ELIspot assay 7d later. Data represents 4 
similar experiments using 24 recipient mice; ±sem. (c) Female B6 mice were 
immunised with male donor 129 splenocytes treated with either DMSO or 
tunicamycin for ~2hrs. IFN-  response by TH cells to pHY/Ab and pHX/Ab was 
determined 7d later as described above. Data represents 2 similar experiments 
using 12 recipient mice; ±sem. (d) Female B6 mice were immunised with male 
donor 129 splenocytes incubated in either nutrition-rich medium or HBSS for 3hrs 
and IFN-  response by TH cells to pHY/Ab and pHX/Ab was assessed 7d later as 
above. Data represent 2 similar experiments using 12 recipient mice; ±sem. (e) 
Protein extracts from SV40 TAg-transformed wild type, TAP-/- and 2m-/- kidney 
fibroblast lines were separated by SDS-PAGE, transferred onto PVDF membrane 
and probed with LC3- and GADPH-specific mAbs.   
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Figure 16. Inhibition of macroautophagy in donor does not negatively affect 
indirect presentation of class II-restricted HY alloantigen. Female B6 mice 
were immunised with male donor 129 splenocytes incubated in either with 3-MA 
or vehicle (DMSO) for 4hrs and IFN-  response by TH cells to pHY/Ab and 
pHX/Ab was assessed 7d later as above. Data represent 1 experiment using 6 
recipient mice; ±sem. 
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autophagy led to a slightly increased TH cell response to indirect presentation of 
class II HY. Together, these data discount a role for enhanced ERAD and 
autophagy in explaining the impact of TAP and ERAAP on indirect presentation 
of cytosolic antigens. If anything, the data argue that, if autophagy is enhanced 
by TAP or ERAAP deficiency, it would destroy and not protect cytoplasmic 
antigens for indirect presentation by class II molecules.  
As proteasomal degradation is enhanced by ERAD (270), we tested whether 
proteolysis within the cytosol of donor cells impacted indirect antigen 
presentation. If enhanced ERAD was the cause for the phenotype then 
proteasome inhibition should abrogate TH cell responses to HY. Conversely, if 
cytosolic degradation, rather than ERAD, was the mechanism, then proteasome 
inhibition should recapitulate the TAP and ERAAP effect. Thus, B6 mice were 
immunized with male 129 splenocytes that were treated for 2hr with either DMSO 
or the selective proteasome inhibitor epoxomicin (273, 274) and TH cell 
responses were monitored. Surprisingly, in contrast to the negative outcome of 
immunisation with tunicamycin-treated cells, we found that irreversible 
proteasome inhibition of donor cells resulted in a two-fold increase in TH cell 
responses to pHY when compared to that elicited by donor cells containing 
functional proteasomes (Figure 17a).  
Thus, proteasomes negatively impact indirect presentation and the intact 
form of the HY alloantigen is perhaps donated to recipient CD8 + DCs for indirect 
presentation. Contrary to this, proteasomal inhibition of donor cells negatively 
affected CTL responses to class I-restricted H60 and H4b, suggesting that 
 90 
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Figure 17. Proteasomes regulate indirect presentation of the class II-
restricted pHY alloantigen. (a) B6 female mice were immunised with either 
DMSO (vehicle)- or epoxomicin-treated male donor 129/SvJ splenocytes. After 
7d, IFN-  response by TH cells to pHY/Ab and pHX/Ab and by CTL to pH60/Kb, 
pH4b/Kb and SV40 epi IV/Kb was determined by ex vivo ELISpot assay. Data 
represent 5 similar experiments using ~2—3 recipient mice per group per 
experiment; ±sem. (b) 129/SvJ male donor splenocytes were treated for 2 hours 
with either DMSO (vehicle) or epoxomicin. B6 and B6.129-LMP2-/- female mice 
were immunised with extensively washed male donor 129/SvJ splenocytes. After 
7d, IFN-  response TH cells to pHY/Ab and pHX/Ab was assessed by ex vivo 
ELISpot assay. Data represent 2 similar experiments using ~3 recipient mice per 
group per experiment; ±sem.   
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perhaps proteasomal product is donated to recipient CD8 + DCs for cross-
presentation (Figure 17a).  
 If intact antigen is donated for indirect presentation, then it may require 
processing within recipient DCs. Because recipient TAP and ERAAP influenced 
indirect presentation of pHY, we reasoned that the recipient‘s proteasomes may 
be involved. Thus, immunisation of female B6.129-LMP2-/- mice with male 129 
splenocytes resulted in a tempered TH response to pHY/Ab (Figure 17b). 
Surprisingly however, the TH response to pHY/Ab was completely lost if the donor 
splenocytes were treated with epoxomicin and then transferred into LMP2-
deficient recipient animals (Figure 17b).   
We wanted to test whether antigen in donor cells is affected by lysosomal 
processing and whether donated intact antigen exists in the cytoplasm of 
recipient cells using DCs deficient in the NOX2 component gp91PHOX. NOX2 
activation slows the kinetics of pH lowering during the course of 
endo/phagosomal maturation. Altered pH balance of the phagolysosome caused 
by a deficiency in donor and/or recipient gp91PHOX did not affect TH cell responses 
to pHY/Ab (Figure 18). These data suggest that the increased donation of intact 
HY antigen upon proteasomal inhibition of donor cells requires cytosolic 
processing within the recipient DCs.   
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Figure 18. Donor lysosomes and recipient phagosomes do not participate 
in indirect presentation of the class II-restricted pHY alloantigen. (a) Female 
B6 and B6.129-gp91PHOX-/- mice were immunized with male 129/SvJ splenocytes. 
After 7d, IFN-  response TH cells to pHY/A
b and pHX/Ab was assessed by ex vivo 
ELISpot assay. Data represent 2 similar experiments using 3 recipient mice per 
group per experiment; ±sem. (b) Female B6 and B6.129-gp91PHOX-/- mice were 
immunized with either male B6 or B6.129-gp91PHOX-/- splenocytes. After 7d, IFN-  
response TH cells to pHY/A
b and pHX/Ab was assessed by ex vivo ELISpot 
assay. Data represent 2 similar experiments using 3 recipient mice per group per 
experiment; ±sem. 
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Role for chaperones in indirect presentation of HY alloantigen 
Cross-presentation of class I-restricted antigens requires heat shock proteins 
(82, 275). Because the HY alloantigen is a nucleo-cytoplasmic protein that is 
degraded by donor proteasomes (Figure 17), we reasoned that donor HSP may 
play a role in indirect presentation of this antigen. This possibility was addressed 
in two ways: In the first approach, male 129 splenocytes were treated with 
pharmacologic HSP inhibitors, geldanamycin and KNK437, or DMSO for 2hrs 
and used to immunise B6 mice. Inhibition of HSP90 with either geldanamycin or 
KNK437 tempered TH cell responses against pHY (Figure 19a). This result 
suggested a role for HSP90 in donor cells for indirect presentation of HY 
alloantigen.  
To firm a role for HSP90, in the second approach, we employed mouse 
embryonic fibroblasts (MEF) deficient in heat shock factor protein 1 (Hsf1), a 
transcription factor that regulates the expression of members of the HSP90 
family of heat shock proteins (276). We first generated HY+Hsf1-/- and wild type 
MEF by Dby cDNA transfer because these cells do not otherwise express HY 
mHAg (Figure 19b). Immunisation of B6 mice with HY+Hsf1-/- MEF resulted in 
tempered TH cell responses to HY compared to mice immunized with HY+ wild 
type MEF (Figure 19b). These results imply a critical role for HSP90 in efficient 
indirect presentation of the HY alloantigen.  
Calreticulin (CRT), an ER-resident chaperone, has been implicated in cross-
presentation of class I-restricted antigens (277). Therefore, we determined  
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Figure 19. Donor HSP90, HSP70 and calreticulin facilitate indirect 
presentation of class II-restricted HY alloantigen. (a) B6 female mice were 
immunised with Hsf1-/-Dby+, Hsf1+Dby+ or Hsf1-/-Dby- MEF. After 7d, IFN-  
response by Th cells to pHY/Ab and pHX/Ab was determined by ex vivo ELISpot 
assay. Data represent 2 similar experiments using ~2—3 recipient mice per 
group per experiment; ±sem. (b) Donor 129/SvJ splenocytes were treated with 
pharmacological inhibitors for 3 hours and next extensively washed with PBS. B6 
female mice were immunised with either DMSO (vehicle), geldanamycin (HSP90 
inhibitor) or KNK437 (HSP70 inhibitor) treated male donor 129/SvJ splenocytes. 
After 7d, IFN-  response Th cells to pHY/Ab and pHX/Ab was assessed by ex vivo 
ELISpot assay. Data represent 3 similar experiments using ~2—3 recipient mice 
per group per experiment; ±sem. (c) Female B6 mice were immunised with 
CRT+Dby+, CRT-/-Dby+, CRT+Dby- or CRT-/-Dby- MEF. After 7d, IFN-  response 
by TH cells to pHY/Ab and pHX/Ab was determined as above. Data represent 3 
similar experiments using ~3—4 recipient mice per group per experiment; ± sem.  
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whether CRT expression by donor APC was essential for indirect presentation of 
HY alloantigen. 
For this, we first generated HY+CRT-/- and HY+CRT+ MEF by Dby cDNA 
transfer. Immunisation of B6 mice with HY+CRT-/- MEF resulted in tempered TH 
cell responses to HY compared to mice immunized with HY+CRT+ MEF (Figure 
19c). These results imply a critical role for CRT in efficient indirect presentation of 
the HY alloantigen. 
 
TAP regulates the quantity of class II-restricted antigens displayed 
To test the idea that TAP and ERAAP regulate the quantitative aspects of class 
II-restricted antigen presentation, we determined the response of two distinct 
H3ba mHAg-specific TH cell lines, LPa/B10-B6 and LPa/B10-line. Akin to HY, the 
H3ba mHAg is also derived from a cytoplasmic protein, ribosome binding protein-
1 (RRBP1; AC Brown, GJ Christianson and DC Roopenian, in preparation). 
Moreover, the H3ba-reactive T cell lines allowed us to address the direct role of 
TAP and ERAAP in class II-restricted cytosolic antigen presentation 
independently of any potential indirect effect TAP and ERAAP might have on 
responder T cells in the intact mouse.  
Thus, LPa/B10-B6 and LPa/B10-line were stimulated with B6, B6.129-TAP-/-, 
C.B10-H2b, B.129-TAP-/- or 129/SvJ splenocytes for 48 hrs and the number of 
IFN- + spots determined. The data revealed that B6.129-TAP-/- splenocytes, 
compared to B6 splenocytes, induced 7—8-fold greater number of IFN- + spots 
from the two H3ba-specific TH clones (Figure 20). 
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Figure 20. TAP affects the quantitative aspects of the direct presentation of 
class II-restricted H3ba mHAg. H3ba-specific T helper clones LPa/B10-line and 
LPa/B10-B6 were directly stimulated with the indicated numbers of B6, B6.129-
TAP-/-, C.B10-H2b, B.129-TAP-/- or 129/SvJ splenocytes. After 48hrs, IFN-  
response by the TH clones was determined by ELISpot assay. Data represent 2 
similar experiments; ±sem. 
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This response was antigen-specific because the two TH cell clones did not 
respond to negative control C.B10-H2b, B.129-TAP-/- and 129/SvJ splenocytes 
(Figure 20). Thus, TAP and ERAAP regulate the quantity of class II-restricted 
antigen presentation.  
 
TAP- and ERAAP-deficiency uncovers novel class II-restricted self and 
tumour antigens 
The data so far indicate that TAP and ERAAP impact the quantity of class II-
restricted antigens. Therefore, I reasoned that TAP may affect the quality of class 
II-restricted epitopes, i.e., TAP-deficiency might reveal novel class II epitopes, 
which are absent in wild type cells. In order to address this question, we tested 
SV40 large T-antigen derived peptide library consisting of ~140 15-mer peptides 
with 10 amino acid overlap between them. Immune TH cells from wild type and 
TAP-deficient recipients were stimulated with the library of overlapping peptides. 
Results revealed a distinct pattern of TH cell reactivity to wild type and TAP-
deficient APC (Figure 21). This suggests that distinct peptides were recognized 
by TH cells, implying that TAP can completely destroy potential class II-restricted 
epitopes. 
We next sought to determine the extent of potential changes in class II-
restricted peptide repertoire presented by wild type and TAP-deficient 
professional APCs. These changes were determined by the characteristics of 
naturally processed ligands eluted from class II molecules. 
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Figure 21. TAP and ERAAP deficiency unravels novel class II-restricted TH 
cell epitopes derived from SV40 T-antigen. (a) B6 and B6.129-TAP-/- mice 
were immunised with TAP-deficient SV40 TAg-transformed cell line TAP-/-/ 
WT/19. After 14 days, immune splenocytes were stimulated ex vivo for ~48 hours 
with B6-129- 2m-/- or B6-129-Ab-/- APC pulsed with a panel of 140 15-mer 
peptides that overlap by 10 amino acid residues and span TAg. The resulting 
IFN-  response was monitored by ELIspot assay. Data represents 5 similar 
experiments using 150 recipient mice; ± sem (standard error of mean). (b) B6 
and B6.129-TAP-/- derived immune splenocytes resulting from immunisation with 
TAP-/-/WT/19 were stimulated with B6-129- 2m-/- or B6-129-Ab-/- APC pulsed with 
the indicated doses of peptides that activated TAg-reactive TH cells described 
above. The resulting IFN-  response was monitored by ELIspot assay. Data 
represents 2 similar experiments using 55 recipient mice; ± sem (standard error 
of mean). 
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The eluted peptides were separated by reversed-phase HPLC. Each 
resulting fraction was subjected to mass spectrometric analysis in order to obtain 
peptide sequences. Next, peptide sequences were compared between those 
associated with H2Ab molecules expressed by wild type, TAP- and ERAAP-
deficient cells to look for potential similarities and differences. Preliminary results 
revealed distinct and overlapping peptides from the three samples, suggesting 
that TAP and ERAAP affect quality of class II-restricted peptide repertoire (data 
not shown). Thus, TAP and ERAAP-specific class II-restricted peptides could be 
recognized as non-self by TH cells derived from wild type mice. 
 
TAP and ERAAP impact the TH cell TCR repertoire  
The differences in the self-peptide repertoire between wild type and TAP- and 
ERAAP-specific class II-restricted epitopes led us to ask the question whether 
such changes could potentially result in altered TH TCR repertoire. Potential 
alterations in the TH TCR repertoire could be a result of changes during the 
process of thymic positive and negative selection as these processes are 
controlled by the quality and quantity of self-peptides presented by the MHC 
molecules (278, 279).  
Thus, CDR3  region diversity of purified CD4+ T cells was determined by 
spectratyping and compared between wild type, TAP- and ERAAP-deficient 
CD4+ T cells. CDR3 regions in the V -J  rearrangements were either identical 
between the three comparators, demonstrated altered length distribution (loss or 
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addition of unique sizes), or showed alterations only in the ratio of individual peak 
heights (Figures 22 and 23). 
These changes in CDR3 TCR regions indicate that TAP and ERAAP have 
profound effect on the TH cell TCR repertoire. The impact of such changes in 
response to challenge to pathogens, tumour cells and alloantigens remains to be 
determined. 
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Figure 22. TAP and ERAAP deficiency alters CD4+ T cell repertoire. CDR3  
region diversity of the indicated, randomly selected TCRs expressed by highly 
(MACS enriched followed by FACS purification) purified CD4+ T cells was 
analysed by spectratyping and compared between wild type, TAP- and ERAAP-
deficient T cells. Electrophoretograms from one such experiment are shown. 
Black, wild type CD4+ T cells; blue, TAP-/- CD4+ T cells; red, ERAAP-/- CD4+ T 
cells. These electrophoretograms were used to generate the schematic 
representation of the different patterns of CDR3  diversity. FACS purified CD4+ T 
cells were pooled from several sorts and used for spectratyping experiment. 
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Figure 23. CDR3  regions of CD4+ T cell repertoire greatly differs due to 
TAP and ERAAP deficiency. (a) CDR3  region diversity of the indicated, 
randomly selected TCRs expressed by highly purified (MACS enriched followed 
by FACS purification) CD4+ T cells was analysed and compared between wild 
type, TAP- and ERAAP-deficient T cells. Electrophoretograms representing 
different patterns identified in (b) are shown. (b) CDR3 regions in the indicated 
V -J  rearrangements were either identical between the three comparators, 
demonstrated altered length distribution (loss or addition of unique sizes), or 
showed alterations only in the ratio of individual peak heights. These patterns 
were characterized for each of the V -J  pairings analysed and represented 
schematically; based on data represented in Figure 22. 
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Discussion 
We show that indirect presentation of class II-restricted antigens is mediated 
by CD8 + donor and recipient DCs. Within these cells, proteasomes, TAP, and 
ERAAP, but not tapasin, significantly impact indirect presentation of class II-
restricted antigens, which results in an increased TH cell response to cytoplasmic 
alloantigens (HY and H3ba) and bacterial (L. monocytogenes) antigens. Based 
on this, the class I-processing machinery may affect indirect presentation of 
cytoplasmic antigens in other cases as well- further investigation could produce 
new examples for such an effect. Therefore, the impact of the class I-processing 
pathway on indirect presentation of cytoplasmic antigens might be a general 
regulatory process.  
Both the donor and recipient CD8 + DCs need to be deficient in TAP and 
ERAAP in order to measure their effect on indirect presentation. Donated 
antigens need to escape to the cytoplasm of the recipient CD8 + DC upon 
ingestion of allogeneic, tumour or infected cells. The resulting TH cell response 
revealed not only quantitative differences in response to reported class II 
antigens, but our studies revealed novel SV40 large T antigen derived and self-
antigens in TAP- and ERAAP-deficient professional APCs. TAP and ERAAP 
could lead to complete destruction of self-class II epitopes, thus leading to 
altered CD4+ T cell selection. Such altered class II epitopes could potentially 
affect TH cell responses to microbial and tumour antigens, which may be absent 
in wild type mice. In agreement with this, novel SV40 large T antigen class II 
epitopes were identified. Therefore, novel TH cell responses could be elicited 
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against such antigens which may lead to increased microbial clearance and 
effective removal of tumour cells. Therefore, TAP and ERAAP regulate the 
quality and quantity of the class II-associated self (mHAgs) and non-self (listerial 
and TAg) peptide repertoire.  
Based on changes in class II-restricted peptide repertoire, we observed 
altered CDR3  TCR regions in TAP- and ERAAP-deficient CD4+ T cells, 
suggesting that TAP and ERAAP may have an effect on the TH cell TCR 
repertoire. The impact of such changes in response to challenge to pathogens, 
tumour cells and alloantigens remains to be determined. 
Inhibition of HSP90, as well as the absence of calreticulin negatively 
affected indirect presentation of class II-restricted antigens. Both HSP90 and 
calreticulin are implicated as chaperonins for the donation of cross-presented 
antigens to presenting APC. Therefore, HSP90 and calreticulin may work 
together to chaperone antigens for indirect presentation of class II-restricted 
antigens as well. 
 
Material and Methods 
Mice: All mouse strains, their histocompatibility genotype and sources are 
described in Table 4. All mice were bred, maintained and used in experiments in 
compliance with Vanderbilt University Institutional Animal Care and Use 
Committee regulations and approval.  
Cell lines: Wild type K41 and calreticulin-null K42 MEF (184) as well as Hsf1-null 
MEF (276) were maintained in RPMI-1640 (Cellgro) supplemented with 5% foetal 
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calf serum (FCS; Hyclone), L-glutamine, HEPES and antibiotics (Cellgro). These 
MEFs were transfected with Dby cDNA (229) and selected with 0.5 mg/ml G418 
for ~4 weeks to express the HY alloantigen. Dby expression was verified by RT-
PCR using forward (GGTCTGGAAAAACTGCTGC) and reverse 
(TTGGTGGCATTGTGTCCTGC) primers (229).  
Preparation of donor cells: In some experiments, donor splenocytes were 
treated with PBS or the irreversible proteasome inhibitor epoxomicin or protein 
glycosylation inhibitor/ER stress inducer tunicamycin (Sigma) for 2 or 3hrs, 
respectively, at 37oC. In other experiments, donor splenocytes were starved for 
2hrs in Hanks balanced-salt solution (Cellgro) or maintained in DMEM containing 
10% foetal calf serum, penicillin, streptomycin, L-glutamine, sodium bicarbonate 
and HEPES buffer. Cells were washed thoroughly, resuspended at ~2x108 
cells/ml and used for immunisation. In order to inhibit autophagy, donor cells 
were treated with 3-MA and proteasomal inhibitors for 2 hours, washed and 
resuspended accordingly. 
Peptides: All peptides used in this study (Table 5) were synthesized using Fmoc 
chemistry and determined to be >90% pure by MALDI-MS analysis (The 
Pennsylvania State University College of Medicine, Hershey, PA). Peptide stocks 
and working dilutions were prepared as described (280). SV40 large T antigen 
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Table 4: List of mouse strains used in this study and their immune phenotype 
Mouse strain  
Immune phenotype 
Source/ 
Reference  
Recipient strains  
C57BL/6 Wild type H2
b
 H60
null
 H4
a
 H3b
a
   Jackson Lab 
B6.129-TAP
-/-
  TAP KO introgressed into B6 background; lacks cell 
surface class I expression; does not directly or cross 
present class I-restricted extracellular antigens; do not 
develop CD8 T lymphocytes; H2
b
 H60
null
 H4
a
 H3b
a
  
Jackson Lab 
B6.129-ERAAP
-/-
  ERAAP KO introgressed into B6 background; lacks 
aminopeptidase that trims long peptides to 8—12 amino 
acid residues long ligands that bind class I molecules; H2
b
 
H60
null
 H4
a
 H3b
a
  
This study 
B6.129- 2m
-/-
  2m KO introgressed into B6 background; lacks functional 
H2
b
 class I molecules; H2
b
 H60
null
 H4
a
 H3b
a
  
Jackson Lab 
B6.129-TPN
-/-
  Tapasin KO introgressed into B6 background; lacks 
functional H2
b
 class I molecules; H2
b
 H60
null
 H4
a
 H3b
a
  
(281) 
B6.129-A
b-/-
  H2A
b
 KO introgressed into B6 background; lacks H2
b
 class 
II molecules; deficient in direct and indirect presentation of 
class II-restricted antigens; do not develop conventional 
CD4 T lymphocytes; H2
b
 H60
null
 H4
a
 H3b
a
  
Jackson Lab 
B6.FVB-hDTR
tg
  Cd11c-driven human diphtheria toxin receptor (hDTR) 
transgene introgressed into B6 background; expresses the 
transgene within CD11c
+
 myeloid cells; DT treatment 
renders them deficient in CD11c
+
 myeloid cells within ~18 
hrs and maintains this state for ~72 hrs; H2
b
 H60
null
 H4
a
 
H3b
a
   
(266) 
B6.129-CD8
-/-
   Lacks CD8 T lymphocytes; H2
b
 H60
null
 H4
a
 H3b
a
   Jackson Lab 
B6.129-IL12
-/-
 No IL-12 production; H2
b
 H60
null
 H4
a
 H3b
a
   Jackson Lab 
B6.129-gp91
PHOX-/- 
NOX2 activation absent in DC; H2
b
 H60
null
 H4
a
 H3b
a
   Jackson Lab 
129-Batf3
-/-
  they lack CD8
+
 DCs;  H2
b
 H60
b
 H4
b
 H3b
b
 (267) 
Donor strains 
129/SvJ Wild type H2
b
 H60
b
 H4
b
 H3b
b
  Jackson Lab 
129S6/SvEvTac Wild type H2
b
 H60
b
 H4
b
 H3b
b
  Taconic 
C.B10-H2
b
  Wild type BALB.B; H2
b
 H60
b
 H4
b
 H3b
b
  Jackson Lab 
BALB.B.129-TAP
-/-
  TAP KO introgressed into BALB.B background; lacks H2
b
 
class I molecules; deficient in direct presentation of class 
I-restricted mHAg; H2
b
 H60
b
 H4
b
 H3b
b
  
This study 
129-ERAAP
-/-
  ERAAP KO introgressed into 129/SvEvTac background; 
H2
b
 H60
b
 H4
b
 H3b
b
  
(136) 
129-A
b-/-
  H2A
b
 KO introgressed into 129/SvJ background; deficient 
in direct presentation of class II-restricted mHAg; H2
b
 
H60
b
 H4
b
 H3b
b
   
This study 
129.FVB-hDTR
tg
  hDTR transgene introgressed into 129/SvJ background; 
H2
b
 H60
b
 H4
b
 H3b
b
  
This study 
Histocompatibility genotypes are indicated in italics 
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peptide library of ~150 peptides was generated using solid-phase technology 
with estimated peptide purity of 70% (Mimotopes, Pepscan Systems, Australia). 
Each peptide is 15 amino acid residues long and there is 10 amino acid overlap 
between subsequent peptides (Table 6). 
Immunisation and ELISpot assay: Recipient mice were immunised i.p. with 
2x107 donor splenocytes. After seven days, splenocytes were prepared and used 
in ELISpot assay. For this, Immobilon-P plates (Millipore) were activated and 
coated with 1—2 g/mL IFN-  capture monoclonal antibody (mAb; AN18; 
eBiosciences) overnight. Excess mAb was washed and blocked with 10% FCS in 
RPMI-1640. Meanwhile, 2.5—3x105 red blood cell-free immune splenocytes were 
stimulated with the indicated concentrations of peptides (see Table 6) in 
triplicate. After 48hrs, plates were washed first with Ca2+- and Mg2+-free PBS and 
then with PBS containing 1% FBS and 0.05% Tween-20. Cytokine spots were 
detected with 1 g/mL IFN- -specific biotinylated mAb (R4-6A2; eBiosciences). 
After ~3hrs at room temperature, excess mAb was washed away and Vectastain 
ABC peroxidase (Vector Laboratories) was added to each well. Spots were 
visualised by reacting 2.2-dimethyl-formamide and 3-amino-9-ethylcarbazole with 
30% hydrogen peroxide (Sigma). Spots were counted using CTL ImmunoSpot 
analyzer and CTL ImmunoSpot software, version 3.2 (Cellular Technology).  
The response of H3ba-specific CD4 T cell clones, LPa/B10-B6 and LPa/B10-
line, was determined by stimulating ~105 cells with increasing numbers of 
splenocytes isolated from the indicated mouse strains at 1:1; 1:2.5; 1:5; and 1:10  
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Table 5: List of peptides used in this study 
 Antigen H2 restriction Epitope sequence Reference 
1 HY Ab NAGFNSNRANSSRSS (229) 
2 HX Ab SSSFSSSRASSSRSG 
3 H60 Kb LTFNYRNL (282) 
4 H4a Kb SGTVYIHL (218, 283) 
5 H4b Kb 
P
SGIVYIHL 
6 SV40 epi-IV Kb VVYDFLKL (272) 
7 LLO(190-201) Ab NEKYAQAYPNVS (268) 
8 LLO(318 329) Ab AFDAAVSGKSVS 
9 LLO(253–264) Ab QIYYNVNVNEPT 
10 p60(177–188) Ab TTQATTPAPKVA 
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ratio of responder to stimulator. After 48hrs, IFN- -secreting cells were detected 
by ELISpot assay as described above.   
DC depletion: Vehicle (PBS) or diphteria toxin (DT) (Sigma) was administered 
i.p. to hemizygous hDTRtg mice at 4ng/g body weight as previously described. 
After 18—24hrs, vehicle- or DT-treated mice were used either as recipients or to 
isolate donor splenocytes for immunisation. Flow cytometry analysis in pilot 
experiments and of donor hDTRtg splenocytes indicated that DT-treated mice 
were depleted of >90% splenic CD11c+ cells within 18hrs and remained in this 
state for ~72hrs (266).    
L. monocytogenes infection: To elicit primary CD4+ T cell responses, mice 
were inoculated retro-orbitally with ~5x104 cfu L. monocytogenes. After 12—14d, 
the response of 0.5—1x106 immune splenocytes to L. monocytogenes-derived 
peptide epitopes was determined by ELISpot assay as described above. To 
determine secondary CD4+ T cell responses, mice were inoculated i.p. with ~103 
cfu L. monocytogenes in 0.2 ml PBS or with PBS alone. After 14 days, mice were 
boosted i.p. with ~106 cfu and analyzed 14d later by ELISpot assay. For this, 
0.5—1x106 non-immune and immune splenocytes were stimulated with a panel 
of class II-restricted L. monocytogenes-derived peptide epitopes or negative 
control peptides (see Table 5). 
Peptide isolation and fractionation: Each group, consisting of splenocytes 
harvested from ~70 mice, were used as a source of class II-restricted peptides. 
C57BL/6, B6.129-TAP-/-, B6.129-ERAAP-/- and mixed group of B6.129-Ab-/- and 
129-Ab-/- spleens were isolated and grinded in PBS in order to prepare single-cell 
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suspension. Next, cells were washed and kept in Ack lysis buffer to remove RBC. 
Upon removal of buffer, cell pellets were lysed in buffer (50 mM Tris-HCl, 150 
mM NaCl, and 5 mM EDTA, pH8) containing 2% Igepal (NP-40, Sigma), 50 mM 
iodoacetamide (Acros Organics), and mammalian cell protease inhibitor cocktail 
(Sigma) (284). In order to remove cellular and tissue debris, lysates were 
ultracentrifuged at 90K on 4 C for 2 hours. Lysates were next precleared 
overnight on 4 C with normal mouse serum (NMS) and protein A Sepharose 
beads (RepliGen, Waltham, MA). The following day lysates were subjected to 
sequential MHC class II affinity purification using separate columns packed with 
beads bound to: W6/32-irrelevant antibody, and class II-specific antibody 
(Cedarlane, Burlington, NC). Lysates were passed two times over each column. 
The eluates were made to 2.5 M acetic acid and incubated for 20 minutes ina 
boiling bath, and immediately placed on ice (285). Next, samples were 
centrifuged using Centricon 5 ultrafilters (Millipore). Frozen filtrates were dried to 
powder under vacuum and stored at -80 C. Concentrated peptides, 
approximately in 100-200 L, were subjected to RP HPLC fractionation. Each 
collected fraction was next analysed using LC/MS/MS in order to obtain high 
quality spectra, which are indicative of peptide sequences.  
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Table 6: List of SV40 large T 
antigen derived peptides used in 
this study 
Name Amino acid sequence 
Tag-1 MDKVLNREESLQLMD 
Tag-2 NREESLQLMDLLGLE 
Tag-3 LQLMDLLGLERSAWG 
Tag-4 LLGLERSAWGNIPLM 
Tag-5 RSAWGNIPLMRKAYL 
Tag-6 NIPLMRKAYLKKCKE 
Tag-7 RKAYLKKCKEFHPDK 
Tag-8 KKCKEFHPDKGGDEE 
Tag-9 FHPDKGGDEEKMKKM 
Tag-10 GGDEEKMKKMNTLYK 
Tag-11 KMKKMNTLYKKMEDG 
Tag-12 NTLYKKMEDGVKYAH 
Tag-13 KMEDGVKYAHQPDFG 
Tag-14 VKYAHQPDFGGFWDA 
Tag-15 QPDFGGFWDATEIPT 
Tag-16 GFWDATEIPTYGTDE 
Tag-17 TEIPTYGTDEWEQWW 
Tag-18 YGTDEWEQWWNAFNE 
Tag-19 WEQWWNAFNEENLFC 
Tag-20 NAFNEENLFCSEEMP 
Tag-21 ENLFCSEEMPSSDDE 
Tag-22 SEEMPSSDDEATADS 
Tag-23 SSDDEATADSQHSTP 
Tag-24 ATADSQHSTPPKKKR 
Tag-25 QHSTPPKKKRKVEDP 
Tag-26 PKKKRKVEDPKDFPS 
Tag-27 KVEDPKDFPSELLSF 
Tag-28 KDFPSELLSFLSHAV 
Tag-29 ELLSFLSHAVFSNRT 
Tag-30 LSHAVFSNRTLACFA 
Tag-31 FSNRTLACFAIYTTK 
Tag-32 LACFAIYTTKEKAAL 
Tag-33 IYTTKEKAALLYKKI 
Tag-34 EKAALLYKKIMEKYS 
Tag-35 LYKKIMEKYSVTFIS 
Tag-36 MEKYSVTFISRHNSY 
Tag-37 VTFISRHNSYNHNIL 
Tag-38 RHNSYNHNILFFLTP 
Tag-39 NHNILFFLTPHRHRV 
Tag-40 FFLTPHRHRVSAINN 
Tag-41 HRHRVSAINNYAQKL 
Tag-42 SAINNYAQKLCTFSF 
Tag-43 YAQKLCTFSFLICKG 
Tag-44 CTFSFLICKGVNKEY 
Tag-45 LICKGVNKEYLMYSA 
 114 
 
Tag-46 VNKEYLMYSALTRDP 
Tag-47 LMYSALTRDPFSVIE 
Tag-48 LTRDPFSVIEESLPG 
Tag-49 FSVIEESLPGGLKEH 
Tag-50 ESLPGGLKEHDFNPE 
Tag-51 GLKEHDFNPEEAEET 
Tag-52 DFNPEEAEETKQVSW 
Tag-53 EAEETKQVSWKLVTE 
Tag-54 KQVSWKLVTEYAMET 
Tag-55 KLVTEYAMETKCDDV 
Tag-56 YAMETKCDDVLLLLG 
Tag-57 KCDDVLLLLGMYLEF 
Tag-58 LLLLGMYLEFQYSFE 
Tag-59 MYLEFQYSFEMCLKC 
Tag-60 QYSFEMCLKCIKKEQ 
Tag-61 MCLKCIKKEQPSHYK 
Tag-62 IKKEQPSHYKYHEKH 
Tag-63 PSHYKYHEKHYANAA 
Tag-64 YHEKHYANAAIFADS 
Tag-65 YANAAIFADSKNQKT 
Tag-66 IFADSKNQKTICQQA 
Tag-67 KNQKTICQQAVDTVL 
Tag-68 ICQQAVDTVLAKKRV 
Tag-69 VDTVLAKKRVDSLQL 
Tag-70 AKKRVDSLQLTREQM 
Tag-71 DSLQLTREQMLTNRF 
Tag-72 TREQMLTNRFNDLLD 
Tag-73 LTNRFNDLLDRMDIM 
Tag-74 NDLLDRMDIMFGSTG 
Tag-75 RMDIMFGSTGSADIE 
Tag-76 FGSTGSADIEEWMAG 
Tag-77 SADIEEWMAGVAWLH 
Tag-78 EWMAGVAWLHCLLPK 
Tag-79 VAWLHCLLPKMDSVV 
Tag-80 CLLPKMDSVVYDFLK 
Tag-81 MDSVVYDFLKCMVYN 
Tag-82 YDFLKCMVYNIPKKR 
Tag-83 CMVYNIPKKRYWLFK 
Tag-84 IPKKRYWLFKGPIDS 
Tag-85 YWLFKGPIDSGKTTL 
Tag-86 GPIDSGKTTLAAALL 
Tag-87 GKTTLAAALLELCGG 
Tag-88 AAALLELCGGKALNV 
Tag-89 ELCGGKALNVNLPLD 
Tag-90 KALNVNLPLDRLNFE 
Tag-91 NLPLDRLNFELGVAI 
Tag-92 RLNFELGVAIDQFLV 
Tag-93 LGVAIDQFLVVFEDV 
Tag-94 DQFLVVFEDVKGTGG 
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Tag-95 VFEDVKGTGGESRDL 
Tag-96 KGTGGESRDLPSGQG 
Tag-97 ESRDLPSGQGINNLD 
Tag-98 PSGQGINNLDNLRDY 
Tag-99 INNLDNLRDYLDGSV 
Tag-100 NLRDYLDGSVKVNLE 
Tag-101 LDGSVKVNLEKKHLN 
Tag-102 KVNLEKKHLNKRTQI 
Tag-103 KKHLNKRTQIFPPGI 
Tag-104 KRTQIFPPGIVTMNE 
Tag-105 FPPGIVTMNEYSVPK 
Tag-106 VTMNEYSVPKTLQAR 
Tag-107 YSVPKTLQARFVKQI 
Tag-108 TLQARFVKQIDFRPK 
Tag-109 FVKQIDFRPKDYLKH 
Tag-110 DFRPKDYLKHCLERS 
Tag-111 DYLKHCLERSEFLLE 
Tag-112 CLERSEFLLEKRIIQ 
Tag-113 EFLLEKRIIQSGIAL 
Tag-114 KRIIQSGIALLLMLI 
Tag-115 SGIALLLMLIWYRPV 
Tag-116 LLMLIWYRPVAEFAQ 
Tag-117 WYRPVAEFAQSIQSR 
Tag-118 AEFAQSIQSRIVEWK 
Tag-119 SIQSRIVEWKERLDK 
Tag-120 IVEWKERLDKEFSLS 
Tag-121 ERLDKEFSLSVYQKM 
Tag-122 EFSLSVYQKMKFNVA 
Tag-123 VYQKMKFNVAMGIGV 
Tag-124 KFNVAMGIGVLDWLR 
Tag-125 MGIGVLDWLRNSDDD 
Tag-126 LDWLRNSDDDDEDSQ 
Tag-127 NSDDDDEDSQENADK 
Tag-128 DEDSQENADKNEDGG 
Tag-129 ENADKNEDGGEKNME 
Tag-130 NEDGGEKNMEDSGHE 
Tag-131 EKNMEDSGHETGIDS 
Tag-132 DSGHETGIDSQSQGS 
Tag-133 TGIDSQSQGSFQAPQ 
Tag-134 QSQGSFQAPQSSQSV 
Tag-135 FQAPQSSQSVHDHNQ 
Tag-136 SSQSVHDHNQPYHIC 
Tag-137 HDHNQPYHICRGFTC 
Tag-138 PYHICRGFTCFKKPP 
Tag-139 RGFTCFKKPPTPPPE 
Tag-140 FKKPPTPPPEPET 
All peptides were synthesised by F-moc 
chemistry; the SV40 T-antigen peptides 
(Tag) were synthesised by Chiron 
Mimotopes  
 116 
 
CD4 T cell spectratyping: CDR3  region diversity of the indicated, randomly 
selected TCRs expressed by highly purified (MACS enriched followed by FACS 
purification) CD4+ T cells was analysed and compared between wild type, TAP- 
and ERAAP-deficient T cells. Electrophoretograms represent different patterns 
which were identified during the analysis. CDR3 regions in the indicated V -J  
rearrangements were detected as patterns for each of the V -J  pairings, 
analysed and represented schematically. CDR3 regions in the indicated V -J  
pairings were analysed using specific primers used in this experiment (Table 7). 
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Table 7: Forward, reverse and run-off primers used for CDR3  
spectratyping 
Forward V  primers 
V 2 TAC AGA CCC CAC AGT GAC TTT GC 
V 3 CTT CTA GGA ATT TTG AAT TCA AAG TCA 
V 4  GCA GGT CCA GTC GAC CCG AAA AT 
V 5 ATT CTG GGT TGT CCA GTC TCC AA 
V 6 CCC TCC AAA CTA TGA ACA AGT GG 
V 8 CAA AAC ACA TGG AGG CTG CAG TCA 
V 9 CAG CCA CTT TTG TGG ATA CTA CGG 
V 14 TTC TTG GGT GTT AGT GCT CAG ACT A 
 
Reverse C  primer 
C  GGG TGG AGT CAC ATT TCT CAG ATC 
 
Run-off Jβ primers 
J 1.1 ACT GTG AGT CTG GTT CCT TTA CC 
J 1.2 AAA GCC TGG TCC CTG AGC CGA AG 
J 1.3 CTT CCT TCT CCA AAA TAG AGC 
J 1.4 GAC AGC TTG GTT CCA TGA CCG 
J 1.5 GAG TCC CCT CTC CAA AAA GCG 
J 1.6 TCA CAG TGA GCC GGG TGC CTG C 
J 2.1 GTG AGT CGT GTT CCT GGT CCG AAG 
J 2.2 CCA GAG TGA GCC GGG TGC CTG C 
J 2.3 GTT CCT GAG CCA AAA TAC AGC G 
J 2.4 GTG CCC GCA CCA AAG TAC AAG 
J 2.5 GTG CCT GGC CCA AAG TAC TGG 
J 2.7 CTA AAA CCG TGA GCC TGG TGC 
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CHAPTER III 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
MHC class II processing pathway displays antigens through direct and indirect 
presentation mechanisms. Direct antigen presentation is dependent on several 
mechanisms which facilitate cytoplasmic antigen supply to the lysosomal 
compartment. Such mechanisms include macro-autophagy, chaperone-mediated 
autophagy (CMA) and, for few reported antigens, by a proteasome and/or TAP-
dependent pathway (20, 21, 76, 84, 86, 87, 260, 286). On the other hand, very 
little, if anything, is known about the mechanism(s) underlying indirect 
presentation by class II molecules. According to the assessment from the 
available literature, exogenous antigens- microbial, tumour and allogeneic- that 
are captured through endocytosis or phagocytosis, are shuttled to the lysosomes 
where resident reductases and proteases mediate antigen processing; such 
processed antigens are subsequently presented by class II molecules (44, 48, 
67, 69). The findings presented here provide new evidence that indirect 
presentation of cytosolic class II-restricted antigens is negatively affected by 
components of class I pathway- proteasomes, TAP and ERAAP, but not tapasin. 
Such new information reveals a previously unappreciated role for class I 
processing machinery in regulating the availability of cytoplasmic antigens for 
indirect presentation by class II molecules. As a result, such process affects 
p/class II presentation and alters the outcome of TH cell responses. Thus, the 
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cellular and biochemical mechanism(s) that underlie indirect presentation of 
cytoplasmic, class II-restricted antigens need to be reexamined and elucidated. 
One of the first questions was which professional APC removes dead or 
dying class II-negative cells and uses derived antigens (microbial, tumour or 
allogeneic) for indirect presentation by class II molecules. Data presented here 
suggest that CD8 + DCs have the capacity for indirect presentation of allogeneic 
HY antigen. Furthermore, donor-derived CD8 + DCs serve as the predominant 
source of DBY-encoded cytoplasmic antigen.  
Interestingly, previous studies have revealed that CD8 + DCs, a minute 
cell population within the immune system, are highly specialized in exogenous 
antigen supply for cross-presentation of class I-restricted antigens and contain 
components of the class I processing pathway (160, 259). Cross-presentation, in 
many cases, requires that foreign antigens escape from the 
endosomes/phagosomes into the cytosol where such antigens become 
substrates for proteasomes and downstream components of the class I pathway 
(287). Therefore, in CD8 + DCs, donated cytoplasmic antigens readily become 
available to components of the class I pathway, raising questions whether such 
process limits/affects antigen supply for the class II processing pathway. The 
answer to this question was not available from previous research efforts.  
My data suggest that TAP, both in donor and recipient CD8 + DCs, 
negatively affects indirect presentation of cytoplasmic HY alloantigen. 
Interestingly, only when TAP was absent from both the donor and recipient did 
we see the 2-3 fold increased TH cell response, suggesting that TAP may 
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transport class II-restricted peptide into the ER lumen, thus limiting its availability 
to the lysosomal compartment (Figure 24 and 25). Such role for TAP transporter 
was not previously described. 
TAP has been demonstrated to most efficiently transport peptides with 
hydrophobic and basic amino acid residues at the carboxyl terminus. Central 
amino acids do not affect affinity for the transporter (288, 289). Therefore, TAP 
has very broad specificity for a large number of proteasomal products, so it is not 
surprising that the TAP heterodimer may bind and transport peptides that do not 
fit within the class I peptide binding groove, but may be more suitable for binding 
to class II molecules instead.  
L. monocytogenes secretes LLO to disrupt the phagosomal membrane 
and allows bacterial escape into the cytosol for proliferation. LLO also ruptures 
plasma membrane to allow bacterial escape to the neighbouring cells (290, 291). 
APCs phagocytose infected, dead or dying class II-negative cells for indirect 
class II antigen presentation (83). Based on my experimental data, TAP was 
suggested to affect indirect presentation of L. monocytogenes LLO and p60 
derived class II-restricted epitopes- pLLO(190–201), pLLO(318–329), p60(177–
188) and pLLO(253–264)- again by having negative effect on indirect 
presentation of cytoplasmic antigens derived from the two virulence factors, LLO 
and p60.   
ERAAP acts downstream of TAP by customizing the amino terminus of 
TAP imported peptides either by trimming them to size, or facilitating their 
complete degradation (136, 137, 142, 292). Therefore, the next question was  
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Figure 24. A proposed mechanism of indirect presentation of cytoplasmic, 
class II-restricted antigens. Donated antigens, stabilized in the complex with 
HSP90 (or CRT) are endocytosed. Such antigens seep into the cytoplasm of 
recipient APC where they are processed within the proteasome and resulting 
peptides are transported via TAP transporter and degraded by ERAAP. 
Alternatively, processed peptides are captured upon entry into the cytoplasm and 
stabilized by HSP70 and transported to the LAMP-2a+ lysosomes through CMA. 
Upon release into the lysosomes, peptides are loaded on class II molecules and 
shipped to the cell surface. Another alternative is that part of the endocytosed 
antigens is directly released into the lysosomes. 
Ag, antigen; CatS, cathepsin S; CMA, chaperone mediated autophagy; ER, 
endoplasmic reticulum; ERAAP, ER-associated aminopeptidase associated with 
antigen processing; GILT- -inducible lysosomal thiol reductase; HSP, heat shock 
protein; LAMP-2a, lysosomal associated membrane protein-2a; Ly, lysosome; 
MHC, major histocompatibility complex; pm, plasma membrane; TAP, transporter 
associated with antigen processing.  
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Figure 25. An alternative mechanism for indirect presentation of 
cytoplasmic, class II-restricted antigens. Donated antigens, stabilized in the 
complex with HSP90 (or CRT) are endocytosed. Such antigens seep into the 
cytoplasm of recipient APC where they are processed within the proteasome and 
resulting peptides are transported via TAP transporter and degraded by ERAAP. 
Alternatively, exogenous antigens are in part trapped by autophagosomes and 
donated to the lysosomes for processing and loading on class II molecules for 
presentation on the cell surface. 
Ag, antigen; CatS, cathepsin S; ER, endoplasmic reticulum; ERAAP, ER-
associated aminopeptidase associated with antigen processing; HSP, heat shock 
protein; Ly, lysosome; MHC, major histocompatibility complex; pm, plasma 
membrane; TAP, transporter associated with antigen processing.  
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whether ERAAP potentially affects cytoplasmic allogeneic HY as well as listerial 
LLO and p60 derived class II antigens by possibly degrading them. My data 
suggest that ERAAP in both donor and recipient exerts a negative effect on 
allogeneic HY antigen presentation leading to greatly reduced TH cell responses. 
Likewise, ERAAP also had a negative effect on indirect presentation of 
cytoplasmic listerial LLO and p60 derived class II antigens- pLLO(190–201), 
pLLO(318–329) and p60(177–188). Interestingly, pLLO(253–264) was not 
affected by ERAAP, suggesting that it could follow a different processing route 
that is independent of ERAAP. 
Despite the fact that TAP and ERAAP negatively affect TH cell responses, 
it is still unclear how this effect is exerted and a mechanism is lacking. It should 
be investigated whether the absence of precursors to veto CTL in TAP-mutants 
may affect TH cell responses to bacterial and alloantigens (293). 
Another question is whether the absence of the recipient CD8+ T cell 
population in TAP-deficient mice could affect spleen architecture akin to B cell 
deficiency (294). This remains to be determined in future research.  
CD8+ T cell-deficiency alters the number of CD4+ T cells. Therefore, 
another question is whether the lack of the CD8+ T cell population is responsible 
for increased TH cell responses to HY alloantigen. In order to address this 
question, immune splenocytes were stimulated with pHY and activated TH cells 
were fluorescently stained for intracellular IFN- . This experiment confirmed an 
increased TH cell response in TAP-knockouts compared to wild type.  
 124 
 
In another experiment, the TH cell response between TAP
-/-, 2m-/- and 
CD8 -/- recipients— all of whom lack CD8+ T cells— was compared and no 
change was observed in the latter two; that is, 2m-/- and CD8 -/- recipients 
responded similarly to wild type recipients. Such result suggests that CTL 
deficiency may not be the reason for an increased TH cell response, because an 
increased response was not found in other class I-deficient strains. 
The next question was whether altered natural killer (NK) cell activity in 
TAP-deficient mice could have caused an increased TH cell response to HY 
alloantigen. Previous studies in TAP-deficient mice have reported a population of 
hyporesponsive NK cells which do not lyse autologous class I-deficient cells 
(295). At the same time, such NK cells indirectly and negatively controlled TH cell 
responses to Toxoplasma gondii (296). Nonetheless, I found that IL-15-deficient 
recipient mice- which lack NK and mature NKT cells- displayed similar TH cell 
response to the alloantogen HY akin to wild type recipients, suggesting that NK 
cells did not cause the increased TH cell response (data not shown).   
Both TAP and ERAAP play a significant role during cross-presentation. 
Cross-presented exogenous antigens readily exit from the 
endosomal/phagosomal compartment to gain access to proteasomes and 
downstream components of the class I pathway (149, 164). On the other hand, 
indirect presentation includes shuttling of exogenous antigens from the 
endosomal/phagosomal compartment to the lysosomes where they are loaded 
on class II molecules (13, 83). Therefore, cross-presentation and indirect 
presentation proceed through distinct, yet partially overlapping routes for antigen 
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supply at the level of endosomes. Thus, internalized exogenous antigens from 
dead or dying cells could be exposed to proteasomes, and TAP- and ERAAP-
mediated processing upon which they become degraded and lost. Such a 
mechanism then explains the observed loss of cytoplasmic allogenic HY and 
listerial antigens in wild type cells. 
The role of donor and recipient proteasomes was investigated using 
pharmacological inhibition and LMP-2 deficient recipient immunoproteasomes. 
Inhibition of donor proteasomes revealed an increased TH cell response in 
recipients, suggesting that DBY encoded RNA helicase is a potential 
proteasomal substrate, and that intact helicase, instead of proteasomal product, 
is predominantly donated for indirect presentation. If the whole protein enters the 
recipients‘ cytoplasm, the question is whether such antigen requires processing 
within immunoproteasomes. 
Supporting evidence that indirectly presented cytoplasmic class II-
restricted antigens enter the cytoplasm in recipient CD8 + DCs stems from 
experimental results with LMP-2-deficient immunoproteasomes. When TH cell 
responses to indirectly presented HY alloantigen were compared between wild 
type and LMP-2 deficient recipients, the wild type response was significantly 
greater compared to knockouts, suggesting that proteasomal processing within 
recipient CD8 + DCs is a prerequisite for an optimal TH cell response. Further 
support for such conclusion came from experiments with pharmacological 
inhibition of donor and LMP-2 deficiency of recipient proteasomes which resulted 
in virtual absence of TH cell responses to HY alloantigen.  
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Notwithstanding, LMP-2 deficiency also causes impairment in T cell 
activation, prevention of T-cell mediated autoimmunity and reduced T cell 
apoptosis upon TNF-  exposure (297, 298). LMP-2 deficient TH cells also 
provided poor help to activated B cells. In sum, these results suggest that lower 
TH cell response to HY alloantigen may be caused by such intrinsic defects within 
LMP-2 deficient TH cells. However, direct comparison of TH cell response 
between LMP-2-null recipients given vehicle (DMSO) or proteasomal inhibitor 
treated donor cells revealed that immunoproteasomes play a significant 
processing role for indirectly presented cytoplasmic antigens. This finding further 
suggests that the donor antigen appears in the recipient cytoplasm and, hence, is 
accessed by the class I antigen processing machinery thereby leading to the loss 
of class II-restricted antigens of cytoplasmic origin.   
The next question we asked was which factors mediate antigen 
chaperoning from donor to recipient CD8 + DC during indirect presentation. 
Previous research had shown that HSP90 shields proteasomal products from 
destruction by cytosolic peptidases. Furthermore, HSP90 stabilizes donor 
antigens in order to facilitate cross-presentation by CD8 + DCs (172, 181). At the 
same time, CRT plays a similar chaperone role during cross-presentation, 
although CRT may have other roles, including relaying apoptosis signals to other 
cells of the immune system (299, 300). Such role may explain poor recipient TH 
cell responses in the absence of CRT. In sum, my data suggest an unexpected 
role for the two prominent chaperones—HSP90 and CRT that facilitate cross 
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presentation by class I molecules—for indirect presentation of the class II-
restricted alloantigen, HY (Figures 24 and 25).  
Additionally, HSP70 is known to facilitate indirect presentation of class II-
restricted antigens (183). Data presented herein confirm such a role for HSP70 in 
partially shielding allogeneic HY antigen (Figure 24). Therefore, indirect 
presentation of class II-restricted HY alloantigen unexpectedly follows the 
established cross-presentation route for class I-restricted antigens by employing 
HSP90 and CRT, but in part also uses HSP70 to facilitate antigen transfer to 
recipient CD8 + DCs (Figure 24 and 25). 
Emerging evidence suggests that macroautophagy and CMA are the main 
sources of cytoplasmic antigens which are fed to the lysosomal compartment for 
processing and loading onto class II molecules (286, 301). Therefore, I 
addressed whether macroautophagy and CMA were mechanistically involved in 
indirect presentation. Surprisingly, induction of macroautophagy in donor cells 
entirely abolished indirect presentation of cytoplasmic HY alloantigen as judged 
by complete lack of TH cell responses in mice that received donor cells in which 
macroautophagy was induced by a 2-hour nutrient starvation. Conversely, 
inhibition of macroautophagy with a pharmacological inhibitor, or with the use of 
conditional Atg5 deficient spleen cells as the donor ((302) and data not shown), 
did not affect class II-restricted HY-specific TH cell responses. On the contrary, 
the measured response was greater in conditional Atg5 deficient compared to 
wild type donors and recipients (see explanation below). Therefore, 
macroautophagy, in the case of class II HY alloantigen, has a detrimental effect 
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on the indirect presentation, suggesting that this cellular process limits the pool of 
available class II-restricted antigens. 
The latter process that has been shown to provide cytosolic antigens for 
class II-restricted presentation is CMA. CMA starts with proteasomal processing 
and requires HSP70 to transfer antigens to LAMP-2a+ lysosomes for loading onto 
class II molecules (21). We suggest that proteasomes process class II-restricted 
HY alloantigen, while HSP70 in part facilitates antigen transfer to recipient CD8 + 
DCs. Furthermore, inhibition of macroautophagy is in turn compensated by an 
increase in CMA (303, 304). Therefore, when donor cells are treated with 
pharmacological inhibitors of autophagy, or, possibly, when donor DCs lack Atg5, 
a compensatory mechanism within DCs greatly upregulates CMA (303, 304). As 
a result, the TH cell response in recipients is enhanced with 3-MA treated or Atg5-
deficient APCs compared to recipients receiving vehicle treated donor cells. 
Therefore, one hypothesis is that, following donation of intact protein, it is 
submitted to proteasomal processing. Next, allogeneic HY alloantigen may be 
sequestered both by HSP70 shuttling antigens to LAMP2a+ lysosomes, or by 
HSP90, which diverts the antigen to the TAP transporter and ERAAP (Figure 24).  
The next question was whether TAP and ERAAP deficiency could uncover 
novel class II-restricted epitopes, which are otherwise completely destroyed by 
aminopeptidase(s). With the use of an overlapping SV40 large T antigen peptide 
library, this hypothesis was put to the test. Data revealed two novel class II-
restricted epitopes in the absence of TAP, while a distinct class II epitope was 
found in wild type but not in TAP-knockout mice. Such experiment revealed novel 
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class II-restricted epitopes recognized only by TAP-deficient TH cells. This finding 
is especially important since cancerous cells often accumulate mutations in TAP, 
rendering the complex ineffective for peptide transport into the ER and 
subsequent reduction or inhibition of class I-restricted CTL response to tumour 
antigens (305-307). 
We next sought to compare the naturally occurring peptides eluted from 
class II molecules expressed by wild type, TAP and ERAAP-deficient 
professional APCs. To determine if there were qualitative differences, in a 
preliminary experiment, H2Ab molecules were affinity purified from wild type, 
TAP- and ERAAP knockout mice and the associated peptides eluted, RP-HPLC 
fractionated and subjected to ESI-MS and MSMS analyses. Preliminary results 
suggest that the resulting peptide sequences revealed that H2Ab molecules 
assemble with an altered class II-restricted peptide repertoire in TAP and ERAAP 
deficient splenocytes as compared to those displayed by wild type cells. Further 
studies will examine these peptides and test the potential role of these peptides 
by comparing TH cell responses among wild type, TAP- and ERAAP-deficient 
animals.  
Another line of experiments investigated differences in TH cell TCR 
repertoire among the three groups—wild type, TAP and ERAAP deficient–by 
spectratyping. These experiments revealed substantial differences, both 
quantitative (as judged by differences in peak height) and qualitative (as judged 
by differences in the number of peaks and in elution time of the different peaks) 
of some of the TCR variable regions of the -chain. A previous study based on 
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serologic typing of T cells reported that the TCR repertoire of TH cells was 
unaltered in TAP deficient mice (261). Our finding does not refute the previous 
report as we found differences within the CDR3  loops and not V  usage. 
Hence, we conclude that the TH cell TCR repertoire is different in TAP and 
ERAAP deficient mice as compared to the TCR repertoire of wild type CD4+ T 
cells. This altered repertoire could partly explain the qualitative and quantitative 
differences in the TH cell response to cytosolic antigens that are indirectly 
presented by class II molecules. 
In sum, proteasomes, TAP and ERAAP regulate the quantity of class II-
restricted allogeneic and listerial peptide repertoire. Furthermore, TAP also 
impacts the quality of the presented class II-restricted peptides, as revealed by 
the presentation of novel SV40 large T antigen and the eluted self-class II-
restricted peptides expressed by TAP and ERAAP mutant cells. These 
differences lead to altered TH cell TCR repertoire in TAP- and ERAAP-deficient 
animals and consequently impact TH cell responses to cytoplasmic class II-
restricted microbial, tumour and allograft antigens.    
 
Future directions 
The research presented in this thesis raises a number of new questions that 
could be addressed in future studies. The first; it will be interesting to determine 
the molecular mechanisms regulating trafficking properties of proteins which give 
rise to class II epitopes- DBY (encodes alloantigen HY), RBP1 (encodes 
alloantigen H3ba) and L. monocytogenes derived p60 (encodes p60(177-188) 
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and p60(253-264)). It is of interest to determine whether these proteins can traffic 
to lysosomes or proteasomes for degradation, to the nucleus (DBY and RBP1), 
or can be shuttled via autophagosomes to lysosomes. The purpose of this series 
of proposed experiments is to provide direct evidence regarding the trafficking 
properties of proteins- DBY, RBP1 and L. monocytogenes p60 in bone marrow 
derived DCs, or alternatively, in the murine M  cell lines RAW 264.7, J774 or DC-
like line KG1.  
The above proteins, either radio-labelled or labelled with His- or Flag-tag, 
could be added to DCs. Such DCs could be used to test for proteasomal 
targeting through polyubiquitilation. Other organelles could be isolated through 
gradient density differential ultracentrifugation and tested for the presence of 
proteins of interest. Therefore, the presence of the added proteins in specific 
fractions could be detected. This approach may help in determining the change 
in the levels of protein of interest in organelles over a period of time. An 
alternative approach could be to transduce target cells with constructs containing 
the above mentioned proteins, instead of adding proteins exogenously. As a 
result, these experiments could provide a better understanding of trafficking and 
processing properties of proteins which give rise to cytoplasmic class II-restricted 
epitopes. Such understanding may facilitate improved vaccine design against 
microbial and tumour antigens, as well as help understand the factors which 
influence resulting TH cell responses to cytoplasmic microbial and tumour 
antigens acquired from non-MHC class II expressing cells. 
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Next one could determine quantitative differences in class II epitope presentation 
by wild type, TAP- and ERAAP-deficient bone marrow DCs (or RAW 264.7, J774 
or DC-like line KG1cell line) by incubating DBY, RBP1 and p60 proteins, or 
transducing cells with constructs containing such proteins. After different times of 
incubation, cells would be lysed, class II molecules isolated by using columns 
containing MHC class II-specific antibodies, as well as irrelevant, control 
antibodies (285). Next, class II-restricted peptides would be eluted using 
reversed-phase RP-HPLC. Next, each collected fraction would be analysed using 
LC/MS/MS in order to obtain high quality spectra, which are indicative of peptide 
sequences. These proposed studies could directly indicate differences in peptide 
presentation by wild type and mutant cells. Such results may provide direct 
evidence that specific components of the class I pathway, TAP and ERAAP, 
negatively affect presentation of cytoplasmic class II-restricted antigens. This 
goal is aimed at providing evidence that could support the hypothesis that listerial 
antigens are also affected by TAP and ERAAP. 
Since quantification using mass spectrometry may be somewhat limited, an 
alternative approach could be employed to examine quantitative differences in 
class II peptide presentation from three types of cells listed above. RP-HPLC 
separated peptide fractions may be used to pulse KbDb-deficient professional 
APC. Peptide pulsed APCs can stimulate TH cells from mice previously 
immunized with minor HAg-disparate donor splenocytes or, in the case of p60, 
from mice challenged with L. monocytogenes. TH cell stimulation can be 
measured using ELIspot assay in order to test differences in T cell responses. 
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TAP- and ERAAP-deficient fractions might induce increased stimulation of 
immune TH cells compared to class II peptides eluted from wild type cells. Such 
result would be direct evidence that ERAAP destroys peptides imported via TAP 
into the ER lumen.  
B cell-mediated immunity plays a crucial part in fighting certain pathogens, 
such as Borrelia burgdorferi and Ehrlichia muris (308-310). Such pathogens elicit 
negligible CTL and unproductive TH cell responses (311). Therefore, a second 
area of future research is aimed at promoting B cell-mediated antibody 
responses by uncovering low abundant or previously not characterized class II-
restricted epitopes that are normally destroyed by concerted action of TAP and 
ERAAP. Such class II epitope(s) may be utilized to boost TH cell responses and 
as a means to ultimately design novel and efficient subunit vaccines. Such 
studies could also benefit from using not only ERAAP, but IRAP-deficient mice. 
In order to define novel class II-restricted epitopes, CD8-/-, CD8-/-;TAP-/- and CD8-
/-;ERAAP-/- mice could be used, or 2m-/- single and double knockouts, in order to 
exclude any minor involvement of CTL responses. Low abundant class II 
epitopes could be isolated from from TAP and ERAAP knockouts using the 
techniques described in previous section, followed by RP-HPLC fractionation and 
mass spectrometry analysis.  
Novel class II epitopes may be used in vaccine design by creating complex 
subunit vaccines consisting of a mixture of  (i) microbial proteins which give rise 
to low abundant and/or previously uncharacterized class II epitopes that are 
normally destroyed by TAP and ERAAP,  (ii) glycoproteins and/or lipoproteins 
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that stimulate B cell responses and antibody production, (iii) glycolipids that 
activate NKT cells and (iv) a TAP inhibitor or an ERAAP-inhibitor (perhaps 
leucine-thiol (292)), in order to prevent degradation of novel class II epitopes and 
increase their presentation by professional APCs.  
To test such an approach, bone marrow-derived murine DCs could be 
incubated with above mixture of agents. The next step would be to inoculate 
experimental animals with the relevant pathogen to test microbial clearance and 
protection by measuring TH and B cell responses. If studies with experimental 
animals yield positive results, such candidate vaccine may be tested on human 
subjects. 
 A third future direction is to investigate the possible role of cryptic class II 
epitopes in the development of keratitis following infection by herpes simplex 
virus. Herpetic stromal keratitis (HSK) is a chronic inflammatory disease and a 
leading cause of blindness in infants resulting from an infection in the mother 
(312, 313). MHC class II-restricted TH cell responses play a critical role in chronic 
HSK (312, 314). Nonetheless, which class II-restricted antigen(s) trigger the 
activation of pathogenic TH cells during HSV infection and how such antigens are 
presented remain poorly defined. I hypothesise that TAP blockade by HSV-
encoded ICP47 alters the processing and presentation of cytoplasmic, class II-
restricted self and viral peptide antigen(s) during herpes infection and activates 
pathogenic TH cell responses that mediate HSK. 
 In order to test this hypothesis, viral peptides associated with HLA-DR1 
(B1*0101) molecules expressed by KG-1 DC-like cells infected with wild type or 
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ICP47-null mutant HSV-1 infected could be isolated and characterized. Since 
pathogenic TH cell responses are observed in HSK, self-peptides associated with 
HLA-DR1 (B1*0101) molecules expressed by uninfected as well as cells infected 
with wild type or ICP47-null HSV-1 would be isolated and characterized. 
Next, one could test whether TAP blockade by ICP47 will result in altered 
TH cell responses to novel HLA-DR1 (B1*0101)-restricted epitopes, thereby 
causing HSK. In order to test this hypothesis, transgenic mice that express both 
human TAP-1 and TAP-2 genes (hTAPtg) could be generated. Next, I would 
determine whether the HSV-1-specific TH cells cross-react with HLA-DR1-
restricted self-peptides presented by uninfected cells or altered self-peptides 
presented upon herpes infection. I would also determine whether infection of 
DR1tg;hTAPtg mice with ICP47-null mutant HSV-1 causes HSK.  
 Upon successful completion of the proposed studies, we would have 
determined whether TAP blockade alters class II-restricted antigen processing 
and presentation under pathologic conditions. We would have also determined 
whether TAP blockade impacts the TH cell responses to cytoplasmic antigens 
encoded by a pathogenic virus.  
 
Finally, one could use a similar approach to identify novel class II antigens 
for another bacterial pathogen. Chronic infection with the bacterial pathogen 
Helicobacter pylori is frequent in humans and causes gastritis which can lead to 
an increased risk of gastric cancer (315-317). H. pylori, which carries the Cag 
pathogenicity island, causes patients to have increased risk of developing gastric 
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cancer (317-320). Recently, it was demonstrated that the cytotoxin-associated 
gene A (CagA) protein carries several class II-restricted TH cell epitopes (317). 
Interestingly, TH cell activation upon exposure to the pathogen causes severe 
gastric pathology and has poor prognostic outcome (315-317, 321, 322).  
 The results of my research could be employed to identify novel H. pylori 
specific class II epitopes derived from secreted or membrane anchored proteins 
which may induce TH cell activation and possibly cause gastric cancer. Since 
research presented here suggests that the class I pathway negatively affects 
presentation of class II-restricted epitopes, human DCs and M  treated with 
ICP47 (TAP inhibitor) or leucine-thiol (ERAAP-inhibitor) could be used in vitro to 
identify low abundant and/or novel class II epitopes derived from H. pylori 
proteins. Upon their identification, the next goal would be to in vitro expand 
reactive TH cell clones which provide information regarding TCR usage. The 
ultimate goal would be to eliminate TH cell clones specific for H. pylori in 
humanized mouse models (and potentially in H. pylori infected patient samples or 
patients themselves) in order to improve prognostic outcome. In order to delete 
such TH cells, MHC II tetramers conjugated with Actinium 225 can be used to 
create an agent for TH cell clonal deletion. Actinium 235 can serve as an alpha-
emitting atomic nanogenerator, capable of single-hit killing from the cell surface 
(323). It is expected that deletion of TH cells would provide better prognostic 
outcome for affected patients. Characterization of novel class II epitopes 
following TAP and/or ERAAP inhibition in patient samples could provide better 
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information regarding low abundant and or novel class II epitopes which may 
provide better protection against H. pylori infection and gastric cancer. 
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